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1. Introduction 
Increased human life expectancy has resulted in larger geriatric population throughout the 
world. Consequently, there is increased prevalence of age-associated neurodegenerative 
diseases including Parkinson’s disease (PD) with serious impact on healthcare. This has 
intensified the scientific research on the pathology and therapy of the central nervous 
system (CNS). Although modern approach in biomedical research has made major 
breakthroughs in understanding the pathological basis of PD, the knowledge about therapy 
is limited. Consequently, PD does not have a permanent cure.  
During recent years, there have been several options for PD therapy including both 
pharmacological and neurosurgical approaches. These strategies are primarily aimed at 
improving the motor symptoms without any major side effects ultimately improving the 
quality of the life of the patient. Drugs such as L-dihydroxyphenyl alanine (levodopa or L-
DOPA) replenish the lost dopamine in the brain in early PD and provide symptomatic relief. 
Apart from L-dopa therapy, other drugs including dopamine receptor agonists, MAO-B 
inhibitors and anti-cholinergic drugs have been utilized in the pharmacotherapy of PD 
(Almeida & Hyson, 2008). But, each class of drugs is limited by potential side effects and motor 
complications with chronic treatment. Further, most PD medications do not effectively tackle 
tremor, postural instability and cognitive deficits. Moreover, most of these drugs are not 
completely effective against degeneration of the remaining dopaminergic neurons (Almeida & 
Hyson, 2008). Due to these serious lacunae, there is a tremendous momentum to develop 
newer treatments involving disease modifying, restorative, possibly curative drugs with lesser 
side effects. Most importantly, these drugs should protect the dying neurons thus preventing 
further neuronal loss. In this direction there have been novel strategies of PD 
pharmacotherapy applicable either as independent therapies or as a supplement with the 
existing therapies. These have been tested in experimental models and although many of these 
molecules show promise, their toxicology, bioavailability and clinical efficacy in human 
subjects needs to be examined thoroughly before application to PD.  
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Neurodegeneration in PD involves multiple pathways such as oxidative stress, mitochondrial 
damage, protein aggregation, neuroinflammation etc. Modern medicine utilizes a well-defined 
chemical molecule(s) for pharmacotherapy which might not be effective against different 
disease pathways. Hence, the challenge is to come up with novel molecules that could 
simultaneously target multiple disease pathways without significant side-effects, be non-toxic 
at higher concentrations and have the ability to cross the blood-brain barrier indicating a 
paradigm shift from monotherapy to multi-therapy based on various targets. Towards this, 
natural phytochemicals which possess medicinal properties are being exploited (Kumar, 2006) 
which has increased the interest in the use of herbal products (Tsao, 2010). Consequently, there 
is increasing support for combination of modern drugs with medicine to evolve better 
therapies. It is interesting to note that although phytochemicals normally function as toxins 
and protect the plant source against damage due to pests and harmful organisms, at the lower 
concentrations consumed by humans, these compounds activate adaptive cellular stress 
responses in vivo (“hormetic mechanisms”) thereby providing cytoprotection against 
exogenous toxins. Such hormetic mechanisms relevant to neuronal survival and improved 
brain function ultimately elevate the levels of antioxidant enzymes, protein chaperones and 
neurotrophic factors (Mattson et al., 2007). Polyphenols from various plant sources form a 
major group of phytochemicals with potential therapeutic and curative properties. 
2. Polyphenols: Structure and biological properties 
Polyphenols are the most widely distributed natural compounds in the plant kingdom. They 
are the secondary metabolites which were originally synthesized to protect the plants 
against microbial attack, pests and ultraviolet radiation. Polyphenols are present in fruits, 
vegetables, oils etc. and provide plants with brilliant colours and fragrance. Polyphenols 
might possess many biologically significant functions with implications for human 
degenerative diseases (Han et al., 2007).  
2.1 Chemistry of Polyphenols 
Polyphenols in general have a phenolic structure with several hydroxyl groups. Natural 
polyphenols vary from simple molecules (viz., phenolic acids) to complex polymeric forms 
(viz., condensed tannins) (Tsao, 2010). Flavonoids are the largest group of polyphenols and 
have been studied extensively. Currently more than 8000 phenolic structures are known and 
among them over 4000 flavonoids have been identified (Bravo, 1998, Cheynier, 2005, 
Harborne &  Williams, 2000).They are classified based on the number of phenolic rings and 
the structural elements that link these rings (Butterfield et al., 2002, Ramassamy, 2006) 
(Figures 1 and 2) as follows:  
a. Phenolic acids: These are non-flavonoid polyphenols that constitute less than 1/3 of the 
phenolic content in our diet and are represented mainly by benzoic acids and cinnamic 
acid derivatives. 
 
 
Fig. 1. Classification of polyphenols. 
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Fig. 2. Chemical structures of common polyphenols. 
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b. Flavonoids: These represent approximately 2/3 of the polyphenolic content in our diet. 
They have the C6-C3-C6 strucural backbone, of which two are phenolic rings named 
Ring A and Ring B, and one chromane ring (Tsao 2010). Flavonoids are further 
classified based on the oxidation state of the chromane ring into Anthocyanins and 
anthoxanthins. Anthoxanthins are further classified into Flavones, Flavonols, 
Flavonones, Isoflavones, Flavanols (D'Archivio et al., 2007).  
c. Stilbenes: Stilbenes are characterized by the presence of 1,2-diphenylethylene nucleus 
with hydroxyl groups substituted on the aromatic rings (Han et al., 2007). The best 
known compound among Stilbenes is trans-resveratrol.  
d. Tannins: Tannins are water soluble polyphenols and are classified into condensed and 
hydrolysable tannins.  
e. Diferuloylmethanes: Diferuloylmethanes are characterized by two aromatic rings 
substituted with hydroxyls, and linked by aliphatic chain containing carbonyl groups. 
Curcumin is one of the best known polyphenol among diferuloylmethanes. 
Most polyphenols are chemically modified by acetylation, hydroxylation, methoxylation. 
These modifications could significantly influence the physicochemical properties and in vivo 
absorption/degradation of the polyphenols. For e.g., acetylated flavonoids (epicatechin, 
epigallocatechin) are absorbed without deconjugation and hydrolysis (Rice-Evans &  Miller 
1996, Scalbert &  Williamson 2000). Similarly, polyphenols with most antioxidant potential 
possess 3- 6 hydroxyl groups. However, hydroxylation in the C3 position significantly 
inhibits the antioxidant activity and chelation of metals (Huguet et al., 1990, van Acker et al., 
1996). Most polyphenols also exist as glycosides with the addition of sugar and acylated 
sugars at different positions of the polyphenolic structure (one to three moieties per 
polyphenol)  (Tsao, 2010). The attached sugar could be either glucose or rhamnose and each 
glycosylation influences the physicochemical properties and intestinal absorption of the 
polyphenol (Rice-Evans &  Miller, 1996, Scalbert &  Williamson, 2000). Accordingly, if 
polyphenols are glycosylated with glucose/galactose, they will be absorbed through the 
small intestine by specific carriers (Scalbert &  Williamson, 2000). Those containing 
rhamnose cannot be absorbed through the small intestine and are degraded by 
rhamnosidases produced by the colonic microflora. Further, glycosylation of polyphenols 
might decrease their antioxidant properties (Fukumoto &  Mazza, 2000).  
2.2 Biological functions of polyphenols 
Polyphenols might ameliorate neurodegeneration mainly via (i) intrinsic antioxidant 
properties and/or by (ii) modulation of cell signalling pathways that control cell survival, 
death and differentiation (Chen et al., 2000, Molina et al., 2003, Shen et al., 2007, Spencer, 
2007).  
2.2.1 Antioxidant properties 
It has been suggested that consumption of foods or beverages which are rich in polyphenols 
can increase the antioxidant levels in vivo (Frankel et al., 1993). Polyphenols can protect 
against cellular oxidative stress by directly scavenging free radicals and by chelation of 
divalent metal ions. The phenolic hydroxyl groups are potent nucleophiles that neutralize 
free radicals and form aroxyl radicals and this is central to the antioxidant properties of 
polyphenols. The antioxidant potential is enhanced by the vicinal hydroxyl groups 
depending on their number and orientation relative to the electron withdrawing groups 
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such as COOH, CH2COOH, or (CH)2CO2CH (Rice-Evans et al., 1996). The radical 
scavenging activity of polyphenols is measured by Trolox (a water soluble -tocopherol 
analog)-equivalent antioxidant capacity (TEAC) assay and expressed as the millimolar 
concentration of Trolox (TEAC=1) equivalent to the activity of a 1 mM solution of the given 
compound (Rice-Evans et al. 1996). Most of the common polyphenols have higher TEAC 
value compared to the endogenous antioxidant glutathione (GSH), whose TEAC is 1.0.  
Since free divalent metal ions such as iron generate free radicals by fenton reaction, 
chelation of free iron by polyphenols protects neurons from oxidative stress (Li et al., 2010) 
with implications for PD and Alzheimer’s disease (AD) (Sahu &  Gray 1997, Sugihara et al., 
1999). Flavonoids protect against oxidative damage either by forming complexes with iron 
or copper or by direct detoxification due to inherent structural characteristics that enhance 
the antioxidant potential (Bors et al., 1990). 
2.2.2 Modulation of cell signalling pathways 
Beyond antioxidant activities, polyphenols such as curcumin, resveratrol, quercetin and 
other flavonoids modulate cellular signalling pathways, that could affect the gene 
expression and interfere with cell death mechanisms (Williams et al., 2004). Polyphenols 
exert modulatory effects on neurons by selectively interacting with protein kinase and lipid 
kinase signalling cascades such as phosphatidylinositol 3-kinase (PI3 kinase or PI3K)/akt, 
tyrosine kinase, protein kinase C (PKC) and Mitogen activated protein kinase (MAPK) 
pathways (Agullo et al., 1997, Gamet-Payrastre et al., 1999, Matter et al., 1992, Schroeter et 
al., 2002, Spencer et al., 2003, Vlahos et al., 1994). Inhibitory or stimulatory actions at these 
pathways immensely affect the cellular functions by altering the phosphorylation states of 
target molecules and/or by modulating gene expression (Spencer, 2007). Many Polyphenols 
bind to ATP binding sites of proteins (Conseil et al., 1998) like PKC (Gamet-Payrastre et al. 
1999, Kantengwa &  Polla, 1991), protein kinase A (PKA) (Revuelta et al., 1997), calcium 
plasma membrane ATPase, mitochondrial ATPase and topoisomerase (Boege et al., 1996). 
For example, the stilbene resveratrol and the citrus flavones, naringenin and hesperetin have 
been shown to inhibit the activity of a number of protein kinases (Spencer 2007). Flavonoids 
and their metabolites can selectively interact within MAPK signalling pathways (Kobuchi et 
al., 1999, Kong et al., 2000).  
a. Extracellular signal-regulated kinase (ERK) pathway: Some flavonoids are found to 
have inhibitory effect on the ERK pathway and some others activate this pathway. 
Flavonoids have close structural homology to specific inhibitors of ERK pathway, such 
as PD98059 (2’–amino-3’-methoxyflavone), which is a selective non-competitive 
inhibitor of the mitogen activated kinase, MEK 1 (Alessi et al., 1995). Flavonoids and 
their metabolites may also act on this pathway in a similar manner. Certain flavonoids 
such as Quercetin and its O-methylated metabolites are shown to induce neuronal 
apoptosis by inhibition of ERK pathway (Spencer 2003). The MEK inhibitor PD98059 
has been shown to effectively block inducible nitric oxide synthase (iNOS) expression 
and generation of nitric oxide (NO) (Bhat et al., 1998), suggesting that flavonoids may 
also be capable of exerting anti-inflammatory actions via inhibitory actions on MEK1 
within the ERK signalling pathway. Studies have indicated that flavanols (Huang et al., 
2005, Li et al., 2004), flavones (Chen et al., 2004, Kim et al., 2001, Lee et al., 2003, Shen et 
al., 2002, Woo et al., 2006), and flavonols (Chen et al., 2005) are all capable of inhibiting 
the release of NO by activated microglia via the down-regulation of iNOS gene 
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expression. Epicatechin (EC), and one of its metabolites, 3’-O–methyl-(–)- epicatechin 
(mEC), have been shown to stimulate phosphorylation of ERK1/2 and the downstream 
transcription factor cAMP response element binding protein (CREB) at physiological 
concentrations (Schroeter et al., 2007). Some polyphenols may act on the ERK pathway 
via acting through steroid-like receptors in neurons to modulate ERK and CREB-
mediated gene expression. For example, resveratrol rapidly activates ERK signalling 
through alpha and beta estrogen receptors (Klinge et al., 2005).  
b. c-Jun-N-terminal kinase (JNK): There are a number of potential sites where flavonoids 
may interact in the JNK pathway. EC and mEC have been shown to protect neurons 
against oxidative damage via a mechanism involving the suppression of JNK, and 
downstream partners, c-jun and pro-caspase-3 (Schroeter et al., 2001). The flavone, 
baicalein, significantly inhibits 6-hydroxydopamine (6-OHDA) induced JNK activation 
and neuronal cell death and quercetin suppresses JNK activity and apoptosis induced 
by hydrogen peroxide (Ishikawa &  Kitamura 2000), 4-hydroxy-2-nonenal (4HNE) 
(Uchida et al., 1999) and tumour necrosis factor-alpha (TNF-┙) (Kobuchi et al. 1999). 
Flavonoids may inhibit the activation of JNK pathway upstream by decreasing 
oxidative stress and maintaining calcium homeostasis (Davis 1999). They may also 
inhibit JNK activation by modulation of the apoptosis signal-regulating kinase 1 (ASK1) 
phosphorylation state, and its association with 14-3-3 protein, which is essential for 
suppression of cellular apoptosis (Zhang, L. et al., 1999). Investigations have indicated 
that flavonoids might have anti-apoptotic property by blocking oxidative stress induced 
activation of caspase-3 in neurons (Schroeter et al. 2001, Schroeter et al., 2000). 
Flavonoid o-quinones, formed from the intracellular oxidation of flavonoids also inhibit 
JNK and other MAPKs via the nucleophilic addition to the cysteine residues of these 
proteins (Spencer et al., 2004). 
c. PI3 kinase pathway: Flavonoids can modulate signalling through the serine/threonine 
kinase, Akt/PKB, one of the main downstream effectors of PI3K in neuronal survival 
(Coffer et al., 1998). Experimental studies suggest that flavonoids inhibit PI3K via direct 
interactions with its ATP binding site. Indeed, one of the most selective PI3K inhibitors 
available, LY294002, was modelled based on the structure of quercetin (Matter et al. 
1992). 
In the current review, we have discussed the properties and therapeutic potential in PD of 
three important polyphenols: cucumin, resveratrol and tea polyphenols.  
3. Curcumin 
Curcumin, the yellow curry spice from the rhizome of turmeric is a polyphenolic compound 
with several beneficiary properties. Chemically characterized to be diferuloylmethane 
(C21H20O6) or 1,6-heptadiene-3,5-dione-1,7-bis(4-hydroxy-3-methoxyphenyl), curcumin 
exists as a group of compounds called curcuminoids.  
3.1 Absorption 
Although curcumin has several beneficial properties in vivo, a major limiting factor is its 
poor bioavailability. Its poor bioavailability is due to insolubility in aqueous media, poor 
absorption, rapid metabolism and fast systemic elimination. Following oral administration 
of curcumin (1.0 g / kg) in mice, 0.13 g / ml was detected in the plasma after 15 min and 
peaked at 0.22 g / ml at 1 hr. Plasma concentration of curcumin however declined to 5 ng / 
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ml at 6 h. Following intraperitoneal administration of curcumin (0.1 g/kg), only 2.25 g / ml 
appeared in the plasma in the first 15 min. Upto 99% of curcumin and 85% of 
tetrahydrocurcumin was conjugated with glucuronide thus limiting their bioavailability. It 
has also been suggested that oral administration of curcumin results in very low absorption 
into the blood. At 1 h time point, the intestine, spleen, liver and kidney had 177.04, 26.06, 
26.90, and 7.51 g/g curcumin respectively, while the brain had as less as 0.41 g / g. Mass 
spectrometry analysis suggested that curcumin was first biotransformed to 
dihydrocurcumin and then tetrahydrocurcumin which were subsequently converted to 
monoglucuronide conjugates (Pan et al., 1999). In a more recent study, curcumin was 
administered orally to rats at 500 mg / kg and the peak curcumin concentration of ~36 mg / 
whole tissue, in the intestine was reached at 1 h time point, while in the blood, liver and 
kidney, peak concentrations were reached at 6 h (Suresh &  Srinivasan 2010). In a pilot 
human trial on cancer patients, the concentration of curcumin in the liver following oral 
administration (450 – 3600 mg/ day for 1 week prior to surgery) was measured. The results 
indicated that only trace levels of curcumin and its metabolites were present in the liver and 
in circulation and the order of magnitude was too less to exert pharmacological effects 
(Garcea et al., 2004). As a result of this constraint, research is now directed towards 
enhancing the bioavailability of curcumin. Animal and human studies suggest that 
administration of curcumin along with piperine / turmeric oil enhances its bioavailability 
(Bishnoi et al., 2010, Suresh &  Srinivasan 2010). Administration of curcumin along with 
piperine enables curcumin to stay for longer in the tissues. When administered with 
piperine, curcumin was detected in the brain at 24, 48 and 96 h and at 48 h the levels of 
curcumin in the brain exceeded that found in the kidney (5.87 g vs 1.16g) (Suresh &  
Srinivasan 2010). More recently, curcumin nanoparticles which are entirely water soluble 
have been suggested to enhance its bioavailability (Ray et al., 2011). Curcumin complexation 
with phosphatidyl choline (PC) and liposomal curcumin PC complex enhanced its 
bioavailability in terms of better absorption and improved pharmacokinetics (Gupta &  Dixit 
2011a, b).  
3.2 Antioxidant properties of curcumin 
The antioxidant activity of curcumin has been attributed to the various functional groups of 
curcumin. Jovanovic et al. suggest that the central methylenic group rather than the 
phenolic group is the H-atom donor, while others attribute its radical scavenging property 
to the phenolic group (Barclay et al., 2000, Priyadarsini et al., 2003) and the methoxy group 
further enhances this activity (Priyadarsini et al. 2003). The interactions between curcumin 
and biological relevant free radicals have been thoroughly investigated. Iwunze and 
McEwan demonstrated by biophysical techniques that curcumin directly detoxified the 
reactive nitrogen species peroxynitrite (PN) (Iwunze &  McEwan 2004). Our group 
demonstrated that curcumin can protect neuronal mitochondria against PN induced 
nitration and nitrosylation of brain mitochondrial proteins (Mythri et al., 2007). It was also 
shown that curcumin protected against PN induced protein nitration and inhibition of 
enzyme activity of mitochondrial complex I with implications for PD (Mythri et al. 2007). 
Recently, we demonstrated that curcumin protects against PN mediated loss of 
mitochondrial membrane potential and mitochondrial integrity and curcumin derivatives 
offered improved protection compared to curcumin (Mythri et al. 2011). Mishra et al 
demonstrated that at low superoxide concentrations, curcumin effectively caused 
superoxide dismutation without itself undergoing any chemical change, but at higher 
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concentrations of superoxide, curcumin inhibited superoxide activity by reacting with it 
(Mishra et al., 2004). The enol structure with the intramolecular hydrogen bond of curcumin 
strongly enhances the free radical scavenging activity (Ohara 2005, Toniolo et al., 2002). In 
vivo, the antioxidant activity of curcumin could be mediated through antioxidant enzymes 
such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx). Curcumin 
has been shown to serve as a Michael acceptor, reacting with GSH and thioredoxin (Adams 
et al., 2005). Curcumin has been found to be at least ten times more active as an antioxidant 
than even vitamin E (Khopde et al., 2000). The phenolic and the methoxy group on the 
phenyl ring and the 1,3-diketone system seem to be important structural features of 
curcumin that can contribute to these effects. The antioxidant activity of curcumin increases 
when the phenolic group has a methoxy group at the ortho position (Motterlini et al., 2000).  
3.3 Intracellular targets 
The important molecular targets of curcumin include growth factors, growth factor 
receptors, transcription factors, transcription factor receptors, cytokines, enzymes and genes 
which regulate apoptosis. Curcumin activates the NF-E2-related factor 2/ Antioxidant 
Response Element (Nrf2/ARE) pathway which in turn induces synthesis of phase II 
antioxidant  (Jeyapaul &  Jaiswal, 2000, Wild et al., 1999), glutathione-S-transferase (GST) 
(Chanas et al., 2002, Ye et al., 2007), NADH quinone oxidoreductase 1 (NQO1) (Ye et al., 
2007) and hemeoxygenase-1 (HO-1). Curcumin suppresses activation of the pro-survival 
transcription factor, nuclear factor kappa B (NFB) by inhibition of IB kinase (Jobin et al., 
1999, Plummer et al., 1999). Suppression of NFB leads to down regulation of cell cycle 
regulatory protein cyclin D1, cyclooxygenase 2 (COX2) and matrix metalloproteinase 9 
(MMP-9) (Shishodia et al., 2005). Curcumin further, suppresses interleukin 6 (IL-6) mediated 
signal transducers and activators of transcription (STAT-3) phosphorylation and its 
subsequent nuclear translocation (Bharti et al., 2003). Curcumin, it has been reported, 
activates the peroxisome proliferator activated receptor  (PPAR ) and hence mediates 
expression of cyclin D1 and epidermal growth factor receptor (EGFR) (Chen &  Xu, 2005). 
Curcumin down regulates the transcription factor, AP-1, by direct interaction with its DNA 
binding motif, (Bierhaus et al., 1997, Huang, T. S. et al., 1991) and also inhibits interleukin 1 
alpha (IL-1┙) and TNF-induced AP-1 activation (Xu, Y. X. et al., 1997). Moreover, curcumin 
targets the JNK pathway preventing JNK 1/2 and c Jun phosphorylation and caspase 3 
activation (Yu et al., 2010). Curcumin probably interferes with the signalling molecules at 
the same level or proximally upstream of MAPKKK level, hence indirectly affects the JNK 
pathway (Chen, Y. R. &  Tan 1998). Furthermore, curcumin induces anti apoptotic genes 
such as Bcl-2 and inhibits iNOS resulting in reduction of ROS, abrogates oxidative stress 
mediated cytochrome c release or caspase 3 activation, significantly increases levels of anti 
apoptotic proteins Bcl-2 and Bcl-xL and decreases levels of pro-apoptotic proteins Bax and 
Bad (Chen, J. et al., 2006, Chen, Y. R. &  Tan 1998). Curcumin treatment causes a 3-7 fold 
increase in the modifier subunit of the GSH synthesizing enzyme, gamma-glutamyl cysteine 
ligase (┛-GCL), in both the neurons and astrocytes (Dale &  Russell 1956, Lavoie, S. et al., 
2009) and enhances GSH levels (Jagatha et al., 2008) probably by enhancing astrocytic efflux 
of GSH (Stridh et al., 2010). In addition, curcumin regulates iron metabolism by activation of 
iron regulatory protein and repression of ferretin, suggesting a role as an iron chelator (Jiao 
et al., 2006, Jiao et al., 2009).  
Curcumin has been used as an antioxidant, antiseptic, anti-inflammatory, antibacterial and 
antitumor agent and has been used against various disorders such as arthritis, 
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cardiovascular diseases, lung fibrosis, gall stone formation, cardiotoxicity, diabetes, wound 
healing, AD and many more (Aggarwal 2006, Sharma et al., 2006). Recent studies have also 
shown curcumin to be protective against cancer (Duvoix et al., 2005), diabetes (Cheng et al., 
2009, Peeyush et al., 2009) and for the reduction of blood cholesterol (Alwi et al., 2008, Ejaz 
et al., 2009, Jang et al., 2008).  Curcumin protects against ischemia induced elevation in 
malondialdehyde (MDA) and lactate dehydrogenase (LDH) release in animal models 
(Dikshit et al., 1995). Faster restoration of muscle architecture upon curcumin treatment in 
injury models is probably mediated via NFB activation (Thaloor et al., 1999).  
3.4 Effects of curcumin in models of PD 
More recently, curcumin has found its role as a therapeutic agent in models of neurological 
disorders such as stroke and AD (Lim et al., 2001, Thiyagarajan &  Sharma 2004, Yang et al., 
2005). Lim et al. have shown that dietary curcumin reduces amyloid pathology, oxidative 
stress and pro-inflammatory markers in transgenic mice, in addition curcumin reduces the 
levels of GFAP, a marker of astrocytic proliferation (Lim et al. 2001). Further, curcumin not 
only prevented formation of abeta aggregates but could also disintegrate preformed 
aggregates by directly binding to plaques (Yang et al. 2005). Curcumin can cross the blood 
brain barrier and is found to be least toxic in human subjects at high doses (Lao et al., 2006, 
Qureshi et al., 1992, Shankar et al., 1980, Shoba et al., 1998). It can detoxify ROS, prevent 
protein aggregation and induce neurogenesis in vivo (Kim, S. J. et al., 2008, Priyadarsini et al. 
2003, Xu, Y. et al., 2007).  
Since PD is a neurological condition involving oxidative and nitrosative stress pathways, 
curcumin can serve as a potential therapeutic molecule for PD. Although thiol reducing 
agents such as GSH have been evaluated for their anti-PD activity, their efficiency is limited 
due to poor ability to cross the blood brain barrier (Bharath et al., 2002). Curcumin on the 
other hand can cross the blood brain barrier and can be administered at higher doses 
without the risk of toxicity. Curcumin treatment protects substantia nigra (SN) neurons, 
improves striatal dopamine levels and chelates Fe2+, following administration of 6-hydroxy 
dopamine (6-OHDA) in rats (Zbarsky et al., 2005). Curcumin treatment abrogates dopamine 
induced striatal neuron cell death (Luo et al., 1999). Curcumin treatment could further 
increase the density of dopaminergic neurons in the SN (Vajragupta et al., 2003). In all these 
studies, protection was afforded only by pretreatment with curcumin prior to 
administration of the toxin. A recent study in our laboratory indicated that chronic dietary 
consumption of turmeric caused an increase in the tyrosine hydroxylase (TH) positive 
neurons in the SN (Mythri et al. 2011). This is consistent with earlier reports suggesting that 
curcumin contributes to neurogenesis (Kim, S. J. et al. 2008, Xu, Y. et al. 2007). Similarly, our 
laboratory also demonstrated that curcumin derivatives with improved bioavailability offers 
better defense against 1-methyl-4-phenylpyridinium (MPP+) in dopaminergic neurons 
(Mythri et al. 2011). 
Curcumin treatment attenuates 3-nitropropionic acid mediated oxidative stress in vivo 
(Kumar, A. et al., 2007). PN is a highly labile reactive nitrogen species which inflicts severe 
cellular damage by nitrosative protein modifications. However, PN mediated nitrosative 
stress and mitochondrial dysfunction were attenuated by pretreatment with curcumin in 
vitro (Mythri et al. 2011). Curcumin mediated protection from PN toxicity is probably due to 
its direct interaction with and inactivation of PN in vitro (Iwunze &  McEwan 2004, Mythri et 
al. 2007) or indirectly by enhancing GSH levels in vivo ((Jagatha et al. 2008, Mythri et al. 
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2007). Curcumin down regulates iNOS which is probably mediated by the cJun/AP-1 
pathway (Brouet &  Ohshima 1995, Chan et al., 1998, Chen, J. et al. 2006). It has been 
suggested that curcumin binding to the AP-1 binding site on the promoter region of iNOS, 
results in its inactivation (Brouet &  Ohshima 1995). Pan et al.  have further reported that 
curcumin reduces iNOS mRNA levels and blocks induction of NFB (Pan, M. H. et al., 
2000). Rajeswari and colleagues have reported an increase in striatal dopamine and 
dihydroxy phenyl acetic acid (DOPAC) levels following curcumin injection in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-injected mice (Rajeswari &  Sabesan 2008). In 
addition curcumin restores mitochondrial membrane potential, causes elevation in Cu-Zn 
SOD and modulates NFB nuclear translocation (Wang, J. et al., 2009a) by inhibition of IL6 
and TNF (Wang, S. L. et al., 2009b). Curcumin treatment inhibits AP-1 pathway by 
prevention of c-Jun phosphorylation (Luo et al. 1999) in addition to inhibition of JNK 
phosphorylation (Sawada et al., 2002, Yu et al. 2010) and caspase 3 activation (Yu et al. 2010). 
It has been reported that curcumin induces anti apoptotic genes such as Bcl-2 and inhibits 
iNOS resulting in reduction of ROS, abrogates oxidative stress mediated cytochrome c 
release or caspase 3 activation, significantly increases levels of anti apoptotic proteins Bcl-2 
and Bcl-xL and decreases levels of pro-apoptotic proteins Bax and Bad (Chen, J. et al. 2006, 
Chen, Y. R. &  Tan 1998). Curcumin induced cytoprotection was probably mediated by the 
Bcl-2 – mitochondria – reactive oxygen species (ROS) – iNOS pathway.  
Oxidative damage of lipids results in the formation of aldehydes such as 4HNE and MDA, 
which can integrate into lipid membranes resulting in disruption of membrane integrity, 
energy crisis and eventually cell death. Increased levels of 4HNE adducts have been 
reported in PD brains (Yoritaka et al., 1996). Lipid peroxidation mediated mitochondrial 
damage and apoptosis were abrogated by curcumin treatment and this was probably by 
checking cytochrome c release and caspase and PARP activation (Zhu et al., 2004). 
Curcumin was further able to protect from 4HNE mediated alterations in mitochondrial 
respiratory function and redox metabolism, cytochrome c release, DNA fragmentation and 
PARP activation in PC12 cells suggesting a protective function against lipid peroxidation 
mediated damage (Raza et al., 2008). 
Interestingly, not only is curcumin an antioxidant molecule but can also increase the levels 
of GSH, an endogenous antioxidant molecule, probably by enhancing astrocytic efflux of 
GSH (Stridh et al. 2010). Results from our laboratory and others have shown that curcumin 
enhances GSH levels in vitro and in vivo (Jagatha et al. 2008, Rajeswari 2006), in addition to 
enhancing the antioxidant enzyme activities of SOD and catalase in the striatum and mid 
brain of MPTP injected mice (Rajeswari 2006). In addition curcumin treatment results in a 3-
7 fold increase in the modifier subunit of the GSH synthesizing enzyme, ┛-GCL, in both the 
neurons and astrocytes (Dickinson et al., 2003, LaVoie, M. J. et al., 2005). Curcumin mediated 
increase in the transcription of GCL genes is probably via regulation of the binding of 
transcription factors to the 12-tetradecanoate 13-acetate (TPA)-responsive elements (TRE) 
and electrophilic response element (EpRE) elements (Dickinson et al. 2003). It further 
activates the Nrf2/ARE pathway which in turn induces synthesis of phase II antioxidant 
enzymes such as GCL (Jeyapaul &  Jaiswal 2000, Wild et al. 1999), GST (Chanas et al. 2002, 
Ye et al. 2007), NQO1 (Ye et al. 2007) and HO-1. We have used diester derivatives of 
curcumin (di-piperoyl, di-valinoyl and di-glutamoyl) with a resultant enhanced protection 
against GSH depletion mediated oxidative stress and toxin induced cell death in a 
dopaminergic neuronal cell line (Harish et al., 2010, Mythri et al. 2011). Particularly the di-
glutamoyl derivative showed maximum protection due to its deesterification following 
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absorption thus providing glutamate as a precursor for GSH synthesis. Thus one could use 
such pro drugs with improved uptake and better radical scavenging properties to combat 
oxidative and nitrosative stress in various neurodegenerative disorders such as PD. 
Curcumin further inhibits aggregation of -synuclein in vitro (Pandey et al., 2008, Wang, M. 
S. et al., 2010) and aggregation of A53T mutant -synuclein in SH-SY5Y cells in a dose 
dependent manner. Curcumin, thus enhances -synuclein solubility rendering them non-
toxic (Pandey et al. 2008). It also exhibits neuro-restorative properties as shown by its ability 
to disintegrate preformed -synuclein fibrils (Ono &  Yamada 2006). Curcumin pre-
treatment resulted in a reduction in aggregation of synphilin-1, a component of Lewy 
neuritis seen during PD, as a function of rotenone induced nitrosative stress, in SH-SY5Y 
dopaminergic cells suggesting its efficacy in ameliorating nitrosative stress induced damage 
(Pal et al. 2011).   
Curcumin has been suggested to regulate proteins involved in iron metabolism. Increased 
brain iron content is a major risk factor for PD pathogenesis. It has been reported that the SN 
of PD brains has increased iron content (Sofic et al., 1988). Not only is iron responsible for 
the production of .OH radical, but also promotes dopamine autooxidation in the SN neurons 
resulting in the release of H2O2 (Ben-Shachar et al., 1995). It has been reported that curcumin 
induces activation of iron regulatory protein and repression of ferretin and a reduction in 
levels of hepcidin, suggesting a role as an iron chelator (Jiao et al. 2006, Jiao et al. 2009).  
Epidemiological studies have suggested that consumption of curcumin by the Asian Indians 
is probably the reason for the low incidence of AD / PD in India when compared to the 
Caucasians (Ganguli et al., 2000). A study exploring the effect of race and age on the 
prevalence of PD reported that there are approximately 40% less melanized nigral neurons 
in Indian brains when compared to Caucasian brains (Muthane et al., 1998). Furthermore, 
there was no change in the number of nigral neurons with advancing age in the Asian 
Indian population (Alladi et al., 2009). Hence the lower prevalence of PD in India despite 
lower numbers of nigral neurons suggests protective mechanism probably related to the 
dietary habits. Chronic consumption of spices such as turmeric provide antioxidant defense 
against various conditions such as diabetes and cancer (Sinha et al., 2003, Srinivasan 2005). 
We have recently demonstrated that chronic dietary consumption of turmeric ameliorated 
the MPTP induced neurotoxicity in mice (Mythri et al. 2011). Although curcumin is the most 
active ingredient of turmeric, it could be more effective in its natural milieu. Also the 
biological properties of natural extracts would probably be mediated by their various 
constituents rather than a single compound. Therefore it would be interesting to study the 
pharmacokinetics and pharmacodynamics of curcumin or the other biologically active 
components of turmeric in order to completely understand its mechanism of action. 
4. Resveratrol 
Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phytoalexin and a stilbenoid derived is a 
naturally occurring polyphenol with strong antioxidant properties (Baur &  Sinclair 2006, 
Fremont 2000). Resveratrol is a dietary polyphenol found in the skin of grapes, raspberries, 
mulberries, pistachios and peanuts under normal conditions and synthesized by other 
medicinal and edible plants under stress conditions (Rocha-Gonzalez et al., 2008, Saiko et 
al., 2008). It exists as cis- and trans- isomers which are either free or bound to glucose 
(Mattivi et al., 1995). The trans- form can undergo isomerisation to the cis- form when 
exposed to ultraviolet irradiation (Lamuela-Raventos et al., 1995). Experimental evidences in 
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vitro and in vivo have demonstrated the pharmacological potential of resveratrol in human 
diseases and aging with curative properties against neurodegenerative diseases (Rocha-
Gonzalez et al. 2008). 
4.1 Absorption of resveratrol 
The oral absorption of resveratrol in humans is thought to occur mainly by transepithelial 
diffusion. However, a major portion of resveratrol administered orally is excreted via feces 
and urine (Wenzel &  Somoza 2005). Following oral ingestion, trans-resveratrol is 
extensively metabolized in the enterocyte before it enters the blood and target organs. Since 
trans-resveratrol is photosensitive it is easily oxidized thus presenting unfavorable 
pharmacokinetics (Frozza et al., 2010). Extensive metabolism in the intestine and liver 
results in the bioavailability of resveratrol to be <1% and dose escalation and repeated dose 
administration does not significantly alter the bioavailability. Metabolic studies, both in 
plasma and in urine, have revealed that resveratrol is modified as glucuronides and sulfates. 
The sulfated and glucuronidated forms appeared within approximately 15 min of entering 
the bloodstream, and moderate consumption of red wine results in serum levels of 
resveratrol that barely reach the micromolar concentrations. In contrast, its metabolites, 
which may be the active principle, circulate in serum for up to 9 h (Saiko et al. 2008). 
However, reduced dihydroresveratrol conjugates, in addition to highly polar but unknown 
products, may account for ~ 50% of resveratrol following oral administration. Apart from 
the metabolism in the intestine and liver, colonic bacterial metabolism also contributes to 
resveratrol bioavailability (Walle 2011). Among these, extremely rapid sulfate conjugation 
by the intestine/liver appears to be the rate-limiting step in resveratrol's bioavailability. 
Although the systemic bioavailability of resveratrol is very low, accumulation of resveratrol 
in epithelial cells along the aerodigestive tract and potentially active resveratrol metabolites 
may still produce in vivo effects (North &  Verdin 2004). Since low bioavailability of 
resveratrol is a major obstacle to biomedical applications, efforts are in progress to improve 
the absorption and slow down its metabolism (Biasutto et al., 2010). Oral and intravenous 
(i.v.) administration of resveratrol in human volunteers revealed that the absorption 
following oral administration of 25 mg oral dose was at least 70%, with peak plasma levels 
of resveratrol and metabolites at 491 ± 90 ng/ml (about 2 M) and a plasma half-life of 9.2 ± 
0.6 h. However, only trace amounts of unchanged resveratrol (<5 ng/ml) could be detected 
in plasma and most of the oral dose was recovered in urine.  
4.2 Effects of resveratrol in models of PD 
Similar to curcumin, the effectiveness of resveratrol is due to its ability to simultaneously 
target multiple pathways and proteins and thus may be effective in restoring homoestasis in 
vivo. The most important property relevant in abrogation of neuronal damage is its 
antioxidant potential. This has been extensively studied in different models and most of 
them refer to the systemic effects (Kovacic &  Somanathan 2010). Experiments from our 
laboratory have showed that resveratrol prevented peroxynitrite mediated nitration of 
mitochondrial proteins and this was significantly higher compared to curcumin (Mythri et 
al. 2007). Apart from its antioxidant properties, resveratrol displays anti-cancer and anti-
inflammatory properties. The anti-cancer properties arise due its ability to inhibit multiple 
target enzymes including kinases, cyclooxygenases, ribonucleotide reductase and DNA 
polymerases. Similarly, resveratrol protects the cardiovascular system against ischemic-
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reperfusion injury, promotes vasorelaxation, protects the endothelium and displays anti-
atherosclerotic properties and other functions thereby strongly supporting its role in 
cardioprotection. Resveratrol displays different properties depending on its concentration 
and also on the target cell and its physiology (Saiko et al. 2008). Resveratrol and its 
derivatives have shown promise in AD therapy and other neurodegenerative disorders 
(Albani et al., 2010) and more specifically on the inhibition of ┚-amyloid peptide aggregation 
(Richard et al., 2011).  
Interestingly, resveratrol-mediated intracellular effects and protective mechanisms might be 
via its effects as an agonist of the sirtuins (also called SIRT or silent information regulator 
two-proteins), which belong to the histone deacetylase family (Pallas et al., 2008, Wang, F. et 
al., 2007, Zhuang et al., 2003). Sirtuins possess NAD+ dependent deacetylase activity and 
mono-ribosyltransferase activity and are found in most organisms (North &  Verdin 2004, 
Yamamoto et al., 2007). SIRT1 is a major modulator of metabolism and displays therapeutic 
properties (Finkel et al., 2009, Harikumar &  Aggarwal 2008, Karuppagounder et al., 2009). It 
has been hypothesized that by activating SIRT1, resveratrol modulates the activity of 
numerous proteins, including peroxisome proliferator-activated receptor coactivator-1alpha 
(PGC-1 alpha), the FOXO family, Akt (protein kinase B) and NFB (Pallas et al., 2009). The 
beneficial effects of resveratrol as an anti-aging compound are believed to be mediated via 
the activation of SIRT1 (Hung et al., 2010).  
Resveratrol administration in adult mice protected the SN dopaminergic neurons and 
striatal dopamine against the neurotoxic effects of MPTP (Anderson et al., 2006, Blanchet et 
al., 2008). Resveratrol administration also significantly protected mice from MPTP-induced 
motor coordination impairment, hydroxyl radical overloading, and neuronal loss with 
implications for PD therapy (Lu et al., 2008). In cell culture, treatment with resveratrol 
protected against MPP+ toxicity and oxidative damage by modulating the apoptotic markers 
(Bournival et al., 2009, Gelinas &  Martinoli 2002). It has also been demonstrated that 
resveratrol effectively blocked the proteolytic cleavage of PKC and kinase activity induced 
by MPP+. In BV-2 microglial cells activated with lipopolysaccharide (LPS), pretreatment 
with resveratrol suppressed pro-inflammatory cytokine production and nitric oxide release. 
It could be surmised that resveratrol protects against the dopaminergic neurodegeneration 
by modulating the PKC dependent proapoptotic signaling pathway and the inflammatory 
response in activated microglia (Gordon , 2010). Resveratrol significantly reversed the toxic 
effects of MPTP by increasing the levels of dopamine and its metabolites, GSH and activities 
of GPx and reducing lipid peroxidation along with enhanced behaviour performance 
indicating that resveratrol could target multiple pathways with therapeutic potential in PD 
(Anandhan et al., 2010). Interestingly, transfection with SIRT1 siRNA blocked MPP+-
induced apoptosis in SH-SY5Y cells indicating that the toxicity of MPP+ was mediated via 
SIRT1 and possibly through the regulation of another pro-apoptotic protein 
BCL2/Adinovirus E1B 19kDa Interacting Protein 2 (BNIP2). In a similar study, Alvira and 
colleagues showed that although resveratrol prevented MPP+ induced death of cortical 
neurons in culture, the effect was not mediated via SIRT1 activation, since sirtinol - a SIRT1 
inhibitor could not attenuate MPP+ toxicity (Alvira et al., 2007). Furthermore MPP+ 
decreased the expression of SIRT1 indicating that the antiapoptotic effects of resveratrol 
against MPP+ are independent of the stimulation of SIRT1 and depend on its antioxidant 
properties.  
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Other in vitro studies have also demonstrated the effects of Resveratrol against different 
neurotoxins (Chao et al., 2008, Okawara et al., 2007, Outeiro et al., 2007). The therapeutic 
role of resveratrol has been demonstrated in 6-OHDA induced in vivo model of PD. 
Ultrastructural analysis showed that resveratrol alleviated 6-OHDA-induced chromatin 
condensation, mitochondrial dysfunction and vacuolization of SN dopaminergic neurons. 
Resveratrol also reduced the levels of COX-2 and TNF-┙ mRNA in the SN suggesting that 
resveratrol exerts its effects via reduced neuroinflammatory reaction (Jin, F. et al., 2008). 
Oral treatment with resveratrol and its liposomal form prevented oxidative damage, 
prevented neuronal damage and restored motor behaviour in a 6-OHDA rat model of PD 
(Khan et al., 2010, Wang, Y. et al., 2011). The study also showed that resveratrol liposome 
offered better therapeutic effect than free resveratrol due to increased bioavailability. 
Oxyresveratrol, a polyhydroxylated stilbene from mulberry showed improved protection 
against 6-OHDA compared to resveratrol owing to its antioxidant activity, blood-brain 
barrier permeability and water solubility (Chao et al. 2008). Pinostilbene, a methylated 
derivative of resveratrol showed improved cellular bioavailability and better defense 
against 6-OHDA neurotoxicity in neuronal cell culture (Chao et al., 2010b). Lee et al. 
demonstrated that resveratrol protected SH-SY5Y neuroblastoma cells from apoptosis 
induced by dopamine (Lee, M. K. et al., 2007). 
Experiments in rat primary midbrain neuron-glia cultures demonstrated that resveratrol 
protected dopaminergic neurons against LPS-induced neurotoxicity in a dose and time-
dependent manner via inhibition of microglial activation and suppression of release of 
proinflammatory factors. The anti-inflammatory effects and therapeutic effects against LPS 
toxicity was attributed to the inhibition of NADPH oxidase-dependent generation of 
reactive oxygen species and attenuation of translocation of the cytosolic subunit (p47) of 
NADPH oxidase to the cell membrane. This mechanism was substantiated when resveratrol 
was not effective in cultures from NADPH deficient mice.  This is also related to an 
attenuation of MAPK and NFB signalling pathways in microglia (Zhang, F. et al., 2010). 
Bureau and colleagues demonstrated that resveratrol reduced apoptotic neuronal cell death 
induced by neuroinflammation in an LPS cell model and strongly decreased the mRNA 
expression of two proinflammatory genes, IL-1┙ and TNF-┙ (Bureau et al., 2008).  
Administration of a botanical extract (Regrapex-R) prepared from whole grape Vitis vinifera 
and Polygonum cuspidatum, enriched with polyphenols including resveratrol, to a drosophila 
transgenic model of PD overexpressing alpha-synuclein caused dose-dependent scavenging 
effects on ROS, protected mitochondria from oxidative damage and improved locomotor 
dysfunction and extended lifespan (Long et al., 2009). Resveratrol was able to protect  
neuronal cells in culture against toxicity arising from two aggregation-prone proteins, the 
AD-involved amyloid-beta (1-42) peptide (Abeta42) and the familiar PD linked alpha-
synuclein (A30P) [alpha-syn(A30P)] (Albani et al., 2009).  
5. Tea polyphenols 
Tea is one of the most frequently consumed beverage of the world. Out of the 2.5 million 
metric tons of dried tea manufactured annually, ~20 % is green tea, which is mainly 
consumed in China and Japan and ~78 % is black tea, which is consumed in Western 
countries (Chen, L. et al., 1997). Although consumption of tea as an ancient beverage and a 
lifestyle habit has been recognized, its potential pharmacological actions beneficial to human 
health have been recently reported (Weinreb et al., 2004). Human epidemiological and 
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animal experiments indicate that consumption of green and black tea might protect the 
brain against aging and reduce the incidence of dementia, AD and PD, which might be one 
of the mechanistic factors underlying the significantly lower rates of age-related 
neurological disorders among Asians compared to European or American populations 
(Mandel, S. A. et al., 2008). Green tea is non-fermented and contains mainly catechins that 
accounts for 30-40% of its dry weight. Catechins are polyphenols that have been suggested 
to contribute to the therapeutic properties of green tea. On the contrary, black and red teas 
are extensively fermented and oolong tea is semi-fermented which catalyzes the oxidation 
and polymerization of catechins thereby reducing their content to 3-10 % of dry weight. The 
catechins from green tea are polyphenols representing flavonoids. The eight major catechins 
of green tea are (+)-catechin (C), (+)-catechin gallate, (+)-gallocatechin, (+)-gallocatechin 
gallate, (-)-epicatechin (EC), (-)-epicatechin gallate (ECG), (-)-epigallocatechin (EGC), and 
(-)-epigallocatechin gallate (EGCG) (+ and – represent cis and trans isomers respectively). 
EGCG is the most abundant catechin (Higdon &  Frei 2003). Green tea in addition to 
catechins contain 2-3% of caffeic acid and 1-6% of amino acids (theanine constitutes about 
50% amino acid content) (Higdon &  Frei 2003). 
5.1 Absorption 
The in vivo metabolism of green tea catechins has been very well documented in humans 
and laboratory animals (Li, C. et al., 2000, Pietta et al., 1998). In humans, orally administered 
catechins are absorbed, metabolized and largely excreted within 24 h. Catechins were 
detected in rat plasma and bile as free or sulphated and glucuronidated conjugates (Harada 
et al., 1999). The bioavailability of green tea polyphenols in vivo depends on the route of 
administration. After intragastric administration of decaffeinated green tea (DGT) (200 
mg/kg) in rats, 13.7 % of EGC and 31.2 % of EC were shown in the plasma, but only 0.1% of 
EGCG was bioavailable (Chen, L. et al. 1997). Intravenous injection of DGT (25 mg/kg) 
showed that, the beta-elimination half-lives of EGCG, EGC, and EC were 212, 45, and 41 min 
respectively (Chen, L. et al. 1997). Recent studies have suggested that the EC metabolites 
such as epicatechin glucuronide and 3’–O-methylated epicatechin glucuronide formed after 
oral ingestion in rats were detectable in the brain (Abd El Mohsen et al., 2002). The results 
from the distribution study suggest that EGCG is mainly excreted through bile, and that 
EGC and EC are excreted through both the bile and urine (Spencer 2003). 
5.2 Antioxidant functions of tea polyphenols 
There is growing evidence that catechins exert protective role in neurodegeneration. Several 
studies have suggested that the potential curative and therapeutic effects of tea polyphenols 
could be attributed to their free radical scavenging capacity. Catechins are powerful 
hydrogen donating antioxidants and scavengers of reactive oxygen and nitrogen species in 
vitro (Lee, S. et al., 2000, Matsuoka et al., 1995, Oliver et al., 1990). Tea polyphenols may also 
regulate antioxidant enzymes like SOD and catalase in mouse striatum (Levites et al., 2001). 
Progressive iron accumulation in SN pars compacta of PD patients is well established and is 
considered to be a major contributor to oxidative stress (Gerlach et al., 1994, Riederer et al., 
1989). Green tea polyphenols can stoichiometrically bind ferric iron to form an inactive iron 
polyphenol complex (Grinberg et al., 1997). In rat brain tissue, green tea and black tea 
extracts were shown to inhibit lipid peroxidation promoted by iron ascorbate in 
homogenates of brain mitochondrial membranes (Levites et al., 2002b). EGCG inhibited 
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paraquat-induced MDA production in rat liver microsomes by scavenging superoxide 
radicals and by iron chelating activity (Liou et al., 2001).  
5.3 Functions of tea and its constituent polyphenols in PD 
Several prospective studies have assessed the association between coffee/tea consumption 
and PD risk, but the results are inconsistent. Kandinov and colleagues carried out a 
retrospective study on 278 consecutive PD patients and assessed the data on smoking and 
coffee or tea consumption and found that disease progression was not affected by cigarette 
smoking, tea or coffee consumption (Kandinov et al., 2007). In contrast, the same group 
demonstrated that cigarette smoking, coffee and tea drinking may protect against PD and 
delay the onset of disease (Kandinov et al., 2009). According to their study in human 
patients, while consumption of more than 3 cups of tea per day delayed the onset of motor 
symptoms by 7.7 years, coffee consumption advanced the age of PD onset by 4.8 years. In a 
related study, Barranco Quintana and colleagues compiled data from human studies carried 
out by different groups and observed a clear protective effect of tea consumption and this 
protective effect was more evident in the Chinese populations (Barranco Quintana et al., 
2009). They also suggest that the low rate of tea consumption among persons with PD could 
provide valuable insight into the pathology. A population based study in ethnic Chinese to 
understand the role of environmental factors and dietary intake demonstrated that while 
there was a dose-dependent protective effect of PD in coffee and tea drinkers and smokers, a 
history of exposure to heavy metals increased the risk of PD (Tan, E. K. et al., 2003). Tan et 
al. observed that while black tea, a caffeine-containing beverage, showed an inverse 
association with PD risk, green tea drinking was unrelated to PD (Tan, Louis C. et al., 2008). 
A study among Finnish subjects indicated that coffee drinking is associated with a lower 
risk of PD and increased tea consumption is associated with a lower risk of PD (Hu et al., 
2007). Since most of these studies are based on survey among PD patients, it would be 
difficult to draw significant conclusions.  
However, experiments in cell and animal models have clearly indicated the therapeutic 
effects of tea extracts and its constituent catechin, EGCG against PD. These curative 
properties might be due to their ability to act as antioxidants, modulators of intracellular 
neuronal signalling, metabolism, cell survival/death genes, and mitochondrial function 
(Mandel, S. A. et al. 2008, Mandel, S. A. et al., 2011). With reference to PD therapy, EGCG 
has a dual therapeutic effect in vivo (Kang et al., 2010). Firstly, EGCG is a naturally occurring 
catechol-O-methyl transferase (COMT) inhibitor which strongly inhibited human liver 
COMT-mediated O-methylation of L-DOPA in a dose-dependent manner and decreased the 
accumulation of 3-O-methyldopa in the plasma and striatum in vivo following oral 
administration of L-DOPA + carbidopa. In addition, EGCG also protected against 
glutamate-induced oxidative cytotoxicity in hippocampal cultures through inactivation of 
the NFB-signaling pathway in vitro and against kainic acid-induced oxidative damage and 
neurodegeneration in the hippocampus in vivo.  
Many studies related to therapeutic effects of tea polyphenols in PD have been carried out in 
the Parkinsonian model involving the neurotoxin 6-OHDA and have obtained varied 
results. Rats treated with black tea either prior to or after 6-OHDA provided significant 
protection in terms of behavioural and motor functions, antioxidant levels, apoptotic 
markers, dopaminergic neuronal numbers and expression of tyrosine hydroxylase (TH). 
However, the degree of improvement in motor and neurochemical deficits was more 
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prominent in 6-OHDA rats pre-treated with the extract (Chaturvedi et al., 2006). Green tea 
polyphenols protected SH-SY5Y neuroblastoma cells against apoptosis induced by 6-OHDA 
as evidenced by lowered apoptotic markers, restoration of mitochondrial integrity, 
decreased oxidative damage and intracellular free Ca2+ and inhibition of auto-oxidation of 6-
OHDA. Further, the cells were protected against 6-OHDA-induced increase in levels of NO 
and protein nitration, and over-expression of neuronal NOS (nNOS) and iNOS. These 
results indicate that green tea polyphenols ameliorate 6-OHDA toxicity via attenuation of 
the ROS-NO pathway (Guo et al., 2005). The same group confirmed these effects against 6-
OHDA in vivo in mid brain and striatum again emphasizing the involvement of the ROS-NO 
pathway (Guo et al., 2007). In order to identify the active ingredient against 6-OHDA, five 
catechins [EGCG, ECG, EGC, EC and (+)-C] representing the most prominent tea 
polyphenols were compared with regard to their effects on 6-OHDA-induced apoptosis in 
PC12 cells and the protective effects of the five catechins were in the order ECG > EGCG > 
EC > (+)-C > EGC and the antiapoptotic activities appear to be structurally related to the 3-
gallate group (Jin, C. F. et al., 2001, Nie et al., 2002). In a related study, it was showed that 
EGCG protected against 6-OHDA via stimulation of PKC and modulation of cell 
survival/cell cycle genes such as Bax, Bad, Mdm2, Bcl-2, Bcl-w, and Bcl-x(L) and also by 
potent antioxidant and iron chelating actions thereby preventing nuclear translocation and 
activation of cell death promoting NFB (Levites et al., 2002a). Since the stability and 
bioavailability of EGCG are restricted, Chao et al. generated and tested a pro-drug 
representing a fully acetylated EGCG (pEGCG) in a PD cell model (Chao et al., 2010a). They 
found that pEGCG displayed improved protection compared to EGCG against 6-OHDA 
toxicity in SH-SY5Y neuroblastoma cells probably via activation of Akt pathway and 
reduced caspase-3 activity. In contrast, when Leaver et al. administered rats with EGCG for 
14 days followed by exposure to 6-OHDA, they observed that EGCG produced subtle 
symptomatic relief in lesioned animals and could not prevent neuronal damage to a 
significant extent (Leaver et al., 2009).  
Tea extracts and EGCG have displayed therapeutic effect in other toxic models of PD. Tea 
extract and EGCG protected against MPTP mediated dopamine loss and neurotoxicity in 
vivo and this effect could be mediated by inhibition of NOS (Choi et al., 2002, Kim, J. S. et al., 
2010, Li, R. et al., 2006). In a related study, it was demonstrated that green tea extract and 
EGCG protected against MPTP neurotoxicity via antioxidant effects and inhibition of 
monoamine oxidase-B (MOAB) (Levites et al. 2001). Mechanistically, green tea polyphenols 
can ameliorate neuronal damage via inhibitory effects on dopamine transporters (DAT), 
through which they block MPP+ uptake and protect dopaminergic neurons against MPP+-
induced injury (Pan, T. et al., 2003). Similarly, Hou et al. (2008) demonstrated that EGCG 
attenuated cell death in PC12 cells induced by the herbicide and PD toxin paraquat (PQ) by 
maintaining mitochondrial membrane potential, inhibiting caspase-3 activity and down 
regulating the expression of pro-apoptotic protein second mitochondrial-derived activator 
of caspase (SMAC) in cytosol. However, in rotenone-treated mesencephalic cultures and 
organotypic striatal cultures, EGCG protected striatal slices to a limited extent by 
counteracting NO production by rotenone but was not significantly effective against 
rotenone toxicity in mesencephalic cultures (Moldzio et al., 2010). 
Green tea could also protect against environmental toxin-induced cell injury and 
neuroinflammation with implications for PD.  Tai and Truong (2010) reported that EGCG 
reduced dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SH-
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SY5Y cells suggesting that EGCG might activate a protective mechanism that might alleviate 
organochlorine pesticide-induced cell injury. Likewise, EGCG also inhibited LPS-activated 
microglial secretion of NO and TNF-┙ through the down-regulation of iNOS and TNF-┙ 
expression thereby protecting against neuroinflammation and injury in dopaminergic 
neurons (Li, R. et al. 2004). The antioxidant property of EGCG is also beneficial against 
protein aggregation in PD. Iron induces toxic aggregation of monomeric alpha synuclein 
leading to neurodegeneration in dopaminergic neurons. In the MPTP model, iron 
accumulation is also linked to NO-dependent mechanism. Mandel et al. showed that EGCG 
prevented the accumulation of iron and alpha-synuclein in SN thereby preventing neuronal 
damage (Mandel, S. et al., 2004). However, green tea and its constituent polyphenols could 
not protect PC12 cells against L-glutamate and MPP+ (Mazzio et al., 2001).  
6. Conclusions 
Most of the drugs currently used in PD therapy replenish the brain dopamine and provide 
symptomatic relief during early PD. However, many patients develop motor complications 
with chronic treatment. Further, these drugs do not slowdown or prevent the progression of 
the disease since their ability to prevent neuronal damage has not been comprehensively 
validated in humans. Therefore, novel therapies with possible curative properties are being 
exploited for adjunctive therapy. It is well documented that neurodegeneration in PD is 
contributed by several interrelated disease pathways but the molecular mechanisms of their 
relationships and their chronology have not been completely understood. Therefore, any 
molecule(s) with therapeutic potential in PD should be simultaneously effective against 
multiple pathways. In this regard, several in vitro and in vivo studies using PD models have 
tested natural antioxidants and molecules for their ability to protect against 
neurodegeneration with implications for therapy. The most prominent are the polyphenolic 
antioxidants obtained from plant sources. Most of these compounds display antioxidant, 
anti-inflammatory and anti-cancer properties, cross the blood-brain barrier and prevent 
neuronal damage in neurological disorders. Recent studies strongly support the clinical 
application of these compounds in PD. The current chapter explores the therapeutic 
potential of polyphenols such as curcumin, resveratrol and tea polyphenols in PD. These 
three polyphenols share common biological properties including antioxidant function, low 
toxicity and therapeutic benefits in the brain of different PD models. The available data 
indeed indicate that these polyphenols could have therapeutic potential in PD. Although 
several studies have been carried out in the recent years, the biological properties and health 
benefits of these polyphenols have not been completely understood. However, the most 
important limiting factor for the therapeutic application of these compounds in PD is their 
limited bioavailability in vivo. Further, the delivery of compounds specifically to mid-brain 
dopaminergic neurons for maximum therapeutic effect has not been completely 
standardized. Apart from this, studies are also needed to test the safety and efficacy in 
humans to translate the experimental results for therapeutic application in PD patients. 
7. Acknowledgements 
This study was financially supported by the Department of Science and Technology (No. 
SR/FT/L-152/2005 to MMSB). RBM is supported by an extended senior research fellowship 
from the Council for Scientific and Industrial Research (CSIR), India. GH is supported by a 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
133 
senior research fellowship from Indian Council for Medical Research (ICMR), India. NR is 
supported by a junior research fellowship from CSIR, India. 
8. References 
Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P & Rice-Evans CA 
(2002) Uptake and metabolism of epicatechin and its access to the brain after oral 
ingestion. Free Radic Biol Med. Vol. 33, No. 12, (Dec 15 2002):pp. (1693-1702),  0891-
5849 (Print) 
Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, Snyder JP, Liotta DC, Jones DP & 
Shoji M (2005) EF24, a novel synthetic curcumin analog, induces apoptosis in 
cancer cells via a redox-dependent mechanism. Anticancer Drugs. Vol. 16, No. 3, 
(Mar 2005):pp. (263-275),  0959-4973 (Print) 
Aggarwal BB, Bhatt, I.D., Ichikawa, H., Ahn, K.S., Sethi, G., Sandur, S.K., Natarajan, C., 
Seeram, N., Shishodia, S. (2006) Curcumin–biological and medicinal properties. in: 
Turmeric: the genus Curcuma,  (ed.), pp (297-368), Taylor and Francis GroupLondon 
Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H & Payrastre B (1997) 
Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-
kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem 
Pharmacol. Vol. 53, No. 11, (Jun 1 1997):pp. (1649-1657),  0006-2952 (Print) 
Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, Martelli G, Colombo L, Manzoni C, 
Salmona M, Caccia S, Negro A & Forloni G (2009) The SIRT1 activator resveratrol 
protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-
synuclein or amyloid-beta (1-42) peptide. J Neurochem. Vol. 110, No. 5, (Sep 
2009):pp. (1445-1456),  1471-4159 (Electronic) 
Albani D, Polito L, Signorini A & Forloni G (2010) Neuroprotective properties of resveratrol 
in different neurodegenerative disorders. Biofactors. Vol. 36, No. 5, (Sep 2010):pp. 
(370-376),  1872-8081 (Electronic) 
Alessi DR, Cuenda A, Cohen P, Dudley DT & Saltiel AR (1995) PD 098059 is a specific 
inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in 
vivo. J Biol Chem. Vol. 270, No. 46, (Nov 17 1995):pp. (27489-27494),  0021-9258 
(Print) 
Alladi PA, Mahadevan A, Yasha TC, Raju TR, Shankar SK & Muthane U (2009) Absence of 
age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to 
lower incidence of Parkinson's disease. Neuroscience. Vol. 159, No. 1, (Mar 3 
2009):pp. (236-245),  0306-4522 (Print) 
Almeida QJ, Hyson HC (2008) The evolution of pharmacological treatment for Parkinson's 
disease. Recent Pat CNS Drug Discov. 2008 Jan;Vol 3, No. 1, (Jan 2008): pp. (50-54). 
Alvira D, Yeste-Velasco M, Folch J, Verdaguer E, Canudas AM, Pallas M & Camins A (2007) 
Comparative analysis of the effects of resveratrol in two apoptotic models: 
inhibition of complex I and potassium deprivation in cerebellar neurons. 
Neuroscience. Vol. 147, No. 3, (Jul 13 2007):pp. (746-756),  0306-4522 (Print) 
Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB & Ernie S (2008) The effect 
of curcumin on lipid level in patients with acute coronary syndrome. Acta Med 
Indones. Vol. 40, No. 4, (Oct 2008):pp. (201-210),  0125-9326 (Print) 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
134 
Anandhan A, Tamilselvam K, Vijayraja D, Kumar NA, Rajasankar S & Manivasagam T 
(2010) Resveratrol attenuates oxidative stress and improves behaviour in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged mice,  
Anderson DW, Bradbury KA & Schneider JS (2006) Neuroprotection in Parkinson models 
varies with toxin administration protocol. Eur J Neurosci. Vol. 24, No. 11, (Dec 
2006):pp. (3174-3182),  0953-816X (Print) 
Barclay LR, Vinqvist MR, Mukai K, Goto H, Hashimoto Y, Tokunaga A & Uno H (2000) On 
the antioxidant mechanism of curcumin: classical methods are needed to determine 
antioxidant mechanism and activity. Org Lett. Vol. 2, No. 18, (Sep 7 2000):pp. (2841-
2843),  1523-7060 (Print) 
Barranco Quintana JL, Allam MF, Del Castillo AS & Navajas RF (2009) Parkinson's disease 
and tea: a quantitative review. J Am Coll Nutr. Vol. 28, No. 1, (Feb 2009):pp. (1-6),  
1541-1087 (Electronic) 
Baur JA & Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat 
Rev Drug Discov. Vol. 5, No. 6, (Jun 2006):pp. (493-506),  1474-1776 (Print) 
Ben-Shachar D, Zuk R & Glinka Y (1995) Dopamine neurotoxicity: inhibition of 
mitochondrial respiration. J Neurochem. Vol. 64, No. 2, (Feb 1995):pp. (718-723),  
0022-3042 (Print) 
Bharath S, Hsu M, Kaur D, Rajagopalan S & Andersen JK (2002) Glutathione, iron and 
Parkinson's disease. Biochem Pharmacol. Vol. 64, No. 5-6, (Sep 2002):pp. (1037-1048),  
0006-2952 (Print) 
Bharti AC, Donato N & Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits 
constitutive and IL-6-inducible STAT3 phosphorylation in human multiple 
myeloma cells. J Immunol. Vol. 171, No. 7, (Oct 1 2003):pp. (3863-3871),  0022-1767 
(Print) 
Bhat NR, Zhang P, Lee JC & Hogan EL (1998) Extracellular signal-regulated kinase and p38 
subgroups of mitogen-activated protein kinases regulate inducible nitric oxide 
synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated 
primary glial cultures. J Neurosci. Vol. 18, No. 5, (Mar 1 1998):pp. (1633-1641),  0270-
6474 (Print) 
Biasutto L, Marotta E, Garbisa S, Zoratti M & Paradisi C (2010) Determination of Quercetin 
and Resveratrol in Whole Blood—Implications for Bioavailability Studies. 
Molecules. Vol. 15, No. 9, 2010):pp. (6570-6579),  1420-3049 
Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, Mackman N, Ziegler 
R & Nawroth PP (1997) The dietary pigment curcumin reduces endothelial tissue 
factor gene expression by inhibiting binding of AP-1 to the DNA and activation of 
NF-kappa B. Thromb Haemost. Vol. 77, No. 4, (Apr 1997):pp. (772-782),  0340-6245 
(Print) 
Bishnoi M, Chopra K, Rongzhu L & Kulkarni SK (2010) Protective Effect of Curcumin and 
its Combination with Piperine (Bioavailability Enhancer) Against Haloperidol-
Associated Neurotoxicity: Cellular and Neurochemical Evidence. Neurotox Res. 
Vol., No. (Nov 13 2010):pp. 1476-3524 (Electronic) 
Blanchet J, Longpre F, Bureau G, Morissette M, DiPaolo T, Bronchti G & Martinoli MG 
(2008) Resveratrol, a red wine polyphenol, protects dopaminergic neurons in 
MPTP-treated mice. Prog Neuropsychopharmacol Biol Psychiatry. Vol. 32, No. 5, (Jul 1 
2008):pp. (1243-1250),  0278-5846 (Print) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
135 
Boege F, Straub T, Kehr A, Boesenberg C, Christiansen K, Andersen A, Jakob F & Kohrle J 
(1996) Selected novel flavones inhibit the DNA binding or the DNA religation step 
of eukaryotic topoisomerase I. J Biol Chem. Vol. 271, No. 4, (Jan 26 1996):pp. (2262-
2270),  0021-9258 (Print) 
Bors W, Heller W, Michel C & Saran M (1990) Flavonoids as antioxidants: determination of 
radical-scavenging efficiencies. Methods Enzymol. Vol. 186, No. 1990):pp. (343-355),  
0076-6879 (Print) 
Bournival J, Quessy P & Martinoli MG (2009) Protective effects of resveratrol and quercetin 
against MPP+ -induced oxidative stress act by modulating markers of apoptotic 
death in dopaminergic neurons. Cell Mol Neurobiol. Vol. 29, No. 8, (Dec 2009):pp. 
(1169-1180),  1573-6830 (Electronic) 
Bravo L (1998) Polyphenols: chemistry, dietary sources, metabolism, and nutritional 
significance. Nutr Rev. Vol. 56, No. 11, (Nov 1998):pp. (317-333),  0029-6643 (Print) 
Brouet I & Ohshima H (1995) Curcumin, an anti-tumour promoter and anti-inflammatory 
agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem 
Biophys Res Commun. Vol. 206, No. 2, (Jan 17 1995):pp. (533-540),  0006-291X (Print) 
Bureau G, Longpre F & Martinoli MG (2008) Resveratrol and quercetin, two natural 
polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. 
J Neurosci Res. Vol. 86, No. 2, (Feb 1 2008):pp. (403-410),  1097-4547 (Electronic) 
Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G & Calabrese V (2002) 
Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr 
Biochem. Vol. 13, No. 8, (Aug 2002):pp. (444),  1873-4847 (Electronic) 
Chan MM, Huang HI, Fenton MR & Fong D (1998) In vivo inhibition of nitric oxide synthase 
gene expression by curcumin, a cancer preventive natural product with anti-
inflammatory properties. Biochem Pharmacol. Vol. 55, No. 12, (Jun 15 1998):pp. 
(1955-1962),  0006-2952 (Print) 
Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, Henderson CJ, 
Wolf CR, Moffat GJ, Itoh K, Yamamoto M & Hayes JD (2002) Loss of the Nrf2 
transcription factor causes a marked reduction in constitutive and inducible 
expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and 
Gstm4 genes in the livers of male and female mice. Biochem J. Vol. 365, No. Pt 2, (Jul 
15 2002):pp. (405-416),  0264-6021 (Print) 
Chao J, Lau WK, Huie MJ, Ho YS, Yu MS, Lai CS, Wang M, Yuen WH, Lam WH, Chan TH 
& Chang RC (2010a) A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-
gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-
hydroxydopamine. Neurosci Lett. Vol. 469, No. 3, (Jan 29 2010a):pp. (360-364),  1872-
7972 (Electronic) 
Chao J, Li H, Cheng KW, Yu MS, Chang RC & Wang M (2010b) Protective effects of 
pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-
induced neurotoxicity in SH-SY5Y cells. J Nutr Biochem. Vol. 21, No. 6, (Jun 
2010b):pp. (482-489),  1873-4847 (Electronic) 
Chao J, Yu MS, Ho YS, Wang M & Chang RC (2008) Dietary oxyresveratrol prevents 
parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med. Vol. 
45, No. 7, (Oct 1 2008):pp. (1019-1026),  0891-5849 (Print) 
Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y & Agrawal AK (2006) 
Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
136 
lesioned rat model of Parkinson's disease. Neurobiol Dis. Vol. 22, No. 2, (May 
2006):pp. (421-434),  0969-9961 (Print) 
Chen A & Xu J (2005) Activation of PPAR{gamma} by curcumin inhibits Moser cell growth 
and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol 
Gastrointest Liver Physiol. Vol. 288, No. 3, (Mar 2005):pp. (G447-456),  0193-1857 
(Print) 
Chen C, Yu R, Owuor ED & Kong AN (2000) Activation of antioxidant-response element 
(ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green 
tea polyphenol components during cell survival and death. Arch Pharm Res. Vol. 23, 
No. 6, (Dec 2000):pp. (605-612),  0253-6269 (Print) 
Chen CJ, Raung SL, Liao SL & Chen SY (2004) Inhibition of inducible nitric oxide synthase 
expression by baicalein in endotoxin/cytokine-stimulated microglia. Biochem 
Pharmacol. Vol. 67, No. 5, (Mar 1 2004):pp. (957-965),  0006-2952 (Print) 
Chen J, Tang XQ, Zhi JL, Cui Y, Yu HM, Tang EH, Sun SN, Feng JQ & Chen PX (2006) 
Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced 
apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis. Vol. 11, No. 6, (Jun 
2006):pp. (943-953),  1360-8185 (Print) 
Chen JC, Ho FM, Pei-Dawn Lee C, Chen CP, Jeng KC, Hsu HB, Lee ST, Wen Tung W & Lin 
WW (2005) Inhibition of iNOS gene expression by quercetin is mediated by the 
inhibition of IkappaB kinase, nuclear factor-kappa B and STAT1, and depends on 
heme oxygenase-1 induction in mouse BV-2 microglia. Eur J Pharmacol. Vol. 521, 
No. 1-3, (Oct 3 2005):pp. (9-20),  0014-2999 (Print) 
Chen L, Lee MJ, Li H & Yang CS (1997) Absorption, distribution, elimination of tea 
polyphenols in rats. Drug Metab Dispos. Vol. 25, No. 9, (Sep 1997):pp. (1045-1050),  
0090-9556 (Print) 
Chen YR & Tan TH (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling 
pathway by curcumin. Oncogene. Vol. 17, No. 2, (Jul 16 1998):pp. (173-178),  0950-
9232 (Print) 
Cheng TC, Lin CS, Hsu CC, Chen LJ, Cheng KC & Cheng JT (2009) Activation of muscarinic 
M-1 cholinoceptors by curcumin to increase glucose uptake into skeletal muscle 
isolated from Wistar rats. Neurosci Lett. Vol. 465, No. 3, (Nov 20 2009):pp. (238-241),  
1872-7972 (Electronic) 
Cheynier V (2005) Polyphenols in foods are more complex than often thought. Am J Clin 
Nutr. Vol. 81, No. 1 Suppl, (Jan 2005):pp. (223S-229S),  0002-9165 (Print) 
Choi JY, Park CS, Kim DJ, Cho MH, Jin BK, Pie JE & Chung WG (2002) Prevention of nitric 
oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's 
disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology. Vol. 23, 
No. 3, (Sep 2002):pp. (367-374),  0161-813X (Print) 
Coffer PJ, Jin J & Woodgett JR (1998) Protein kinase B (c-Akt): a multifunctional mediator of 
phosphatidylinositol 3-kinase activation. Biochem J. Vol. 335 ( Pt 1), No. (Oct 1 
1998):pp. (1-13),  0264-6021 (Print) 
Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D & Di Pietro A (1998) 
Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and 
steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A. Vol. 95, 
No. 17, (Aug 18 1998):pp. (9831-9836),  0027-8424 (Print) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
137 
D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C & Masella R (2007) 
Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita. Vol. 43, No. 
4, 2007):pp. (348-361),  0021-2571 (Print) 
Dale WM & Russell C (1956) A study of the irradiation of catalase by ionizing radiations in 
the presence of cysteine, cystine and glutathione. Biochem J. Vol. 62, No. 1, (Jan 
1956):pp. (50-57),  0264-6021 (Print) 
Davis RJ (1999) Signal transduction by the c-Jun N-terminal kinase. Biochem Soc Symp. Vol. 
64, No. 1999):pp. (1-12),  0067-8694 (Print) 
Dickinson DA, Iles KE, Zhang H, Blank V & Forman HJ (2003) Curcumin alters EpRE and 
AP-1 binding complexes and elevates glutamate-cysteine ligase gene expression. 
FASEB J. Vol. 17, No. 3, (Mar 2003):pp. (473-475),  1530-6860 (Electronic) 
Dikshit M, Rastogi L, Shukla R & Srimal RC (1995) Prevention of ischaemia-induced 
biochemical changes by curcumin & quinidine in the cat heart. Indian J Med Res. 
Vol. 101, No. (Jan 1995):pp. (31-35),  0971-5916 (Print) 
Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M & 
Diederich M (2005) Chemopreventive and therapeutic effects of curcumin. Cancer 
Lett. Vol. 223, No. 2, (Jun 8 2005):pp. (181-190),  0304-3835 (Print) 
Ejaz A, Wu D, Kwan P & Meydani M (2009) Curcumin inhibits adipogenesis in 3T3-L1 
adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr. Vol. 139, No. 5, 
(May 2009):pp. (919-925),  1541-6100 (Electronic) 
Finkel T, Deng C-X & Mostoslavsky R (2009) Recent progress in the biology and physiology 
of sirtuins. Nature. Vol. 460, No. 7255, 2009):pp. (587-591),  0028-0836 
Frankel EN, Waterhouse AL & Kinsella JE (1993) Inhibition of human LDL oxidation by 
resveratrol. Lancet. Vol. 341, No. 8852, (Apr 24 1993):pp. (1103-1104),  0140-6736 
(Print) 
Fremont L (2000) Biological effects of resveratrol. Life Sci. Vol. 66, No. 8, (Jan 14 2000):pp. 
(663-673),  0024-3205 (Print) 
Frozza RL, Bernardi A, Paese K, Hoppe JB, da Silva T, Battastini AM, Pohlmann AR, 
Guterres SS & Salbego C (2010) Characterization of trans-resveratrol-loaded lipid-
core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol. Vol. 
6, No. 6, (Dec 2010):pp. (694-703),  1550-7033 (Print) 
Fukumoto LR & Mazza G (2000) Assessing antioxidant and prooxidant activities of phenolic 
compounds. J Agric Food Chem. Vol. 48, No. 8, (Aug 2000):pp. (3597-3604),  0021-
8561 (Print) 
Gamet-Payrastre L, Manenti S, Gratacap MP, Tulliez J, Chap H & Payrastre B (1999) 
Flavonoids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol. Vol. 32, No. 3, 
(Mar 1999):pp. (279-286),  0306-3623 (Print) 
Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, 
Pandav R, Belle SH & DeKosky ST (2000) Apolipoprotein E polymorphism and 
Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol. Vol. 
57, No. 6, (Jun 2000):pp. (824-830),  0003-9942 (Print) 
Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ 
& Berry DP (2004) Detection of curcumin and its metabolites in hepatic tissue and 
portal blood of patients following oral administration. Br J Cancer. Vol. 90, No. 5, 
(Mar 8 2004):pp. (1011-1015),  0007-0920 (Print) 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
138 
Gelinas S & Martinoli MG (2002) Neuroprotective effect of estradiol and phytoestrogens on 
MPP+-induced cytotoxicity in neuronal PC12 cells. J Neurosci Res. Vol. 70, No. 1, 
(Oct 1 2002):pp. (90-96),  0360-4012 (Print) 
Gerlach M, Ben-Shachar D, Riederer P & Youdim MB (1994) Altered brain metabolism of 
iron as a cause of neurodegenerative diseases? J Neurochem. Vol. 63, No. 3, (Sep 
1994):pp. (793-807),  0022-3042 (Print) 
Gordon,R. (2010). Resveratrol Protects Dopaminergic Neurons in Parkinson’s Disease 
Models by Modulating the PKC-delta Apoptotic Signaling Pathway & Microglial 
Activation (24:763.5) Proceedings of FASEB meeting, 0892-6638, conference 
location, April, 2010 
 
Grinberg LN, Newmark H, Kitrossky N, Rahamim E, Chevion M & Rachmilewitz EA (1997) 
Protective effects of tea polyphenols against oxidative damage to red blood cells. 
Biochem Pharmacol. Vol. 54, No. 9, (Nov 1 1997):pp. (973-978),  0006-2952 (Print) 
Guo S, Bezard E & Zhao B (2005) Protective effect of green tea polyphenols on the SH-SY5Y 
cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radic Biol 
Med. Vol. 39, No. 5, (Sep 1 2005):pp. (682-695),  0891-5849 (Print) 
Guo S, Yan J, Yang T, Yang X, Bezard E & Zhao B (2007) Protective effects of green tea 
polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of 
ROS-NO pathway. Biol Psychiatry. Vol. 62, No. 12, (Dec 15 2007):pp. (1353-1362),  
1873-2402 (Electronic) 
Gupta NK & Dixit VK (2011a) Development and evaluation of vesicular system for 
curcumin delivery. Arch Dermatol Res. Vol. 303, No. 2, (Mar 2011a):pp. (89-101),  
1432-069X (Electronic) 
Gupta NK & Dixit VK (2011b) Bioavailability enhancement of curcumin by complexation 
with phosphatidyl choline. J Pharm Sci. Vol. 100, No. 5, (May 2011b):pp. (1987-
1995),  1520-6017 (Electronic) 
Han X, Shen T & Lou H (2007) Dietary Polyphenols and Their Biological Significance. 
International Journal of Molecular Sciences. Vol. 8, No. 9, 2007):pp. (950-988),  1422-
0067 
Harada M, Kan Y, Naoki H, Fukui Y, Kageyama N, Nakai M, Miki W & Kiso Y (1999) 
Identification of the major antioxidative metabolites in biological fluids of the rat 
with ingested (+)-catechin and (-)-epicatechin. Biosci Biotechnol Biochem. Vol. 63, No. 
6, (Jun 1999):pp. (973-977),  0916-8451 (Print) 
Harborne JB & Williams CA (2000) Advances in flavonoid research since 1992. 
Phytochemistry. Vol. 55, No. 6, (Nov 2000):pp. (481-504),  0031-9422 (Print) 
Harikumar KB & Aggarwal BB (2008) Resveratrol: a multitargeted agent for age-associated 
chronic diseases. Cell Cycle. Vol. 7, No. 8, (Apr 15 2008):pp. (1020-1035),  1551-4005 
(Electronic) 
Harish G, Venkateshappa C, Mythri RB, Dubey SK, Mishra K, Singh N, Vali S & Bharath 
MM (2010) Bioconjugates of curcumin display improved protection against 
glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell 
line: Implications for Parkinson's disease. Bioorg Med Chem. Vol. 18, No. 7, (Apr 1 
2010):pp. (2631-2638),  1464-3391 (Electronic) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
139 
Higdon JV & Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and 
antioxidant functions. Crit Rev Food Sci Nutr. Vol. 43, No. 1, 2003):pp. (89-143),  
1040-8398 (Print) 
Hou RR, Chen JZ, Chen H, Kang XG, Li MG & Wang BR (2008) Neuroprotective effects of (-
)-epigallocatechin-3-gallate (EGCG) on paraquat-induced apoptosis in PC12 cells. 
Cell Biol Int. Vol. 32, No. 1, (Jan 2008):pp. (22-30),  1065-6995 (Print) 
Hu G, Bidel S, Jousilahti P, Antikainen R & Tuomilehto J (2007) Coffee and tea consumption 
and the risk of Parkinson's disease. Mov Disord. Vol. 22, No. 15, (Nov 15 2007):pp. 
(2242-2248),  0885-3185 (Print) 
Huang Q, Wu LJ, Tashiro S, Gao HY, Onodera S & Ikejima T (2005) (+)-Catechin, an 
ingredient of green tea, protects murine microglia from oxidative stress-induced 
DNA damage and cell cycle arrest. J Pharmacol Sci. Vol. 98, No. 1, (May 2005):pp. 
(16-24),  1347-8613 (Print) 
Huang TS, Lee SC & Lin JK (1991) Suppression of c-Jun/AP-1 activation by an inhibitor of 
tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci U S A. Vol. 88, No. 12, 
(Jun 15 1991):pp. (5292-5296),  0027-8424 (Print) 
Huguet AI, Manez S & Alcaraz MJ (1990) Superoxide scavenging properties of flavonoids in 
a non-enzymic system. Z Naturforsch C. Vol. 45, No. 1-2, (Jan-Feb 1990):pp. (19-24),  
0939-5075 (Print) 
Hung CW, Chen YC, Hsieh WL, Chiou SH & Kao CL (2010) Ageing and neurodegenerative 
diseases. Ageing Res Rev. Vol. 9 Suppl 1, No. (Nov 2010):pp. (S36-46),  1872-9649 
(Electronic) 
Ishikawa Y & Kitamura M (2000) Anti-apoptotic effect of quercetin: intervention in the JNK- 
and ERK-mediated apoptotic pathways. Kidney Int. Vol. 58, No. 3, (Sep 2000):pp. 
(1078-1087),  0085-2538 (Print) 0085-2538 (Linking) 
Iwunze MO & McEwan D (2004) Peroxynitrite interaction with curcumin solubilized in 
ethanolic solution. Cell Mol Biol (Noisy-le-grand). Vol. 50, No. 6, (Sep 2004):pp. (749-
752),  0145-5680 (Print) 
Jagatha B, Mythri RB, Vali S & Bharath MM (2008) Curcumin treatment alleviates the effects 
of glutathione depletion in vitro and in vivo: therapeutic implications for 
Parkinson's disease explained via in silico studies. Free Radic Biol Med. Vol. 44, No. 
5, (Mar 1 2008):pp. (907-917),  0891-5849 (Print) 
Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM, Shin SK, Seong CN & Lee MK (2008) 
Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-
fed hamsters. Metabolism. Vol. 57, No. 11, (Nov 2008):pp. (1576-1583),  1532-8600 
(Electronic) 
Jeyapaul J & Jaiswal AK (2000) Nrf2 and c-Jun regulation of antioxidant response element 
(ARE)-mediated expression and induction of gamma-glutamylcysteine synthetase 
heavy subunit gene. Biochem Pharmacol. Vol. 59, No. 11, (Jun 1 2000):pp. (1433-1439),  
0006-2952 (Print) 
Jiao Y, Wilkinson Jt, Christine Pietsch E, Buss JL, Wang W, Planalp R, Torti FM & Torti SV 
(2006) Iron chelation in the biological activity of curcumin. Free Radic Biol Med. Vol. 
40, No. 7, (Apr 1 2006):pp. (1152-1160),  0891-5849 (Print) 
Jiao Y, Wilkinson Jt, Di X, Wang W, Hatcher H, Kock ND, D'Agostino R, Jr., Knovich MA, 
Torti FM & Torti SV (2009) Curcumin, a cancer chemopreventive and 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
140 
chemotherapeutic agent, is a biologically active iron chelator. Blood. Vol. 113, No. 2, 
(Jan 8 2009):pp. (462-469), 1528-0020 (Electronic) 
Jin CF, Shen SR, Sr. & Zhao BL (2001) Different effects of five catechins on 6-
hydroxydopamine-induced apoptosis in PC12 cells. J Agric Food Chem. Vol. 49, No. 
12, (Dec 2001):pp. (6033-6038), 0021-8561 (Print) 
Jin F, Wu Q, Lu YF, Gong QH & Shi JS (2008) Neuroprotective effect of resveratrol on 6-
OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. Vol. 600, No. 1-3, (Dec 
14 2008):pp. (78-82), 1879-0712 (Electronic) 
Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA & Sartor RB (1999) 
Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory 
gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 
Vol. 163, No. 6, (Sep 15 1999):pp. (3474-3483), 0022-1767 (Print) 
Kandinov B, Giladi N & Korczyn AD (2007) The effect of cigarette smoking, tea, and coffee 
consumption on the progression of Parkinson's disease. Parkinsonism Relat Disord. 
Vol. 13, No. 4, (May 2007):pp. (243-245), 1353-8020 (Print) 
Kandinov B, Giladi N & Korczyn AD (2009) Smoking and tea consumption delay onset of 
Parkinson's disease. Parkinsonism Relat Disord. Vol. 15, No. 1, (Jan 2009):pp. (41-46), 
1353-8020 (Print) 
Kang KS, Wen Y, Yamabe N, Fukui M, Bishop SC & Zhu BT (2010) Dual beneficial effects of 
(-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal 
neurodegeneration: in vitro and in vivo studies. PLoS One. Vol. 5, No. 8, 2010):pp. 
(e11951),  1932-6203 (Electronic) 
Kantengwa S & Polla BS (1991) Flavonoids, but not protein kinase C inhibitors, prevent 
stress protein synthesis during erythrophagocytosis. Biochem Biophys Res Commun. 
Vol. 180, No. 1, (Oct 15 1991):pp. (308-314), 0006-291X (Print) 
Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF & Gibson GE (2009) Dietary 
supplementation with resveratrol reduces plaque pathology in a transgenic model 
of Alzheimer's disease. Neurochem Int. Vol. 54, No. 2, (Feb 2009):pp. (111-118), 0197-
0186 (Print) 
Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, Raza SS, Khan A, Javed H, 
Vaibhav K & Islam F (2010) Resveratrol attenuates 6-hydroxydopamine-induced 
oxidative damage and dopamine depletion in rat model of Parkinson's disease. 
Brain Res. Vol. 1328, No. (Apr 30 2010):pp. (139-151), 1872-6240 (Electronic) 
Khopde SM, Priyadarsini KI, Guha SN, Satav JG, Venkatesan P & Rao MN (2000) Inhibition 
of radiation-induced lipid peroxidation by tetrahydrocurcumin: possible 
mechanisms by pulse radiolysis. Biosci Biotechnol Biochem. Vol. 64, No. 3, (Mar 
2000):pp. (503-509), 0916-8451 (Print) 
Kim H, Kim YS, Kim SY & Suk K (2001) The plant flavonoid wogonin suppresses death of 
activated C6 rat glial cells by inhibiting nitric oxide production. Neurosci Lett. Vol. 
309, No. 1, (Aug 17 2001):pp. (67-71), 0304-3940 (Print) 
Kim JS, Kim JM, O JJ & Jeon BS (2010) Inhibition of inducible nitric oxide synthase 
expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in 
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's 
disease. J Clin Neurosci. Vol. 17, No. 9, (Sep 2010):pp. (1165-1168), 1532-2653 
(Electronic) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
141 
Kim SJ, Son TG, Park HR, Park M, Kim MS, Kim HS, Chung HY, Mattson MP & Lee J (2008) 
Curcumin stimulates proliferation of embryonic neural progenitor cells and 
neurogenesis in the adult hippocampus. J Biol Chem. Vol. 283, No. 21, (May 23 
2008):pp. (14497-14505),  0021-9258 (Print) 
Klinge CM, Blankenship KA, Risinger KE, Bhatnagar S, Noisin EL, Sumanasekera WK, Zhao 
L, Brey DM & Keynton RS (2005) Resveratrol and estradiol rapidly activate MAPK 
signaling through estrogen receptors alpha and beta in endothelial cells. J Biol 
Chem. Vol. 280, No. 9, (Mar 4 2005):pp. (7460-7468),  0021-9258 (Print) 
Kobuchi H, Roy S, Sen CK, Nguyen HG & Packer L (1999) Quercetin inhibits inducible 
ICAM-1 expression in human endothelial cells through the JNK pathway. Am J 
Physiol. Vol. 277, No. 3 Pt 1, (Sep 1999):pp. (C403-411),  0002-9513 (Print) 
Kong AN, Yu R, Chen C, Mandlekar S & Primiano T (2000) Signal transduction events 
elicited by natural products: role of MAPK and caspase pathways in homeostatic 
response and induction of apoptosis. Arch Pharm Res. Vol. 23, No. 1, (Feb 2000):pp. 
(1-16),  0253-6269 (Print) 
Kovacic P & Somanathan R (2010) Multifaceted approach to resveratrol bioactivity: Focus on 
antioxidant action, cell signaling and safety. Oxid Med Cell Longev. Vol. 3, No. 2, 
(Mar-Apr 2010):pp. (86-100),  1942-0994 (Electronic) 
Kumar A, Naidu PS, Seghal N & Padi SS (2007) Effect of curcumin on 
intracerebroventricular colchicine-induced cognitive impairment and oxidative 
stress in rats. J Med Food. Vol. 10, No. 3, (Sep 2007):pp. (486-494),  1096-620X (Print) 
Kumar V (2006) Potential medicinal plants for CNS disorders: an overview. Phytother Res. 
Vol. 20, No. 12, (Dec 2006):pp. (1023-1035),  0951-418X (Print) 
Lamuela-Raventos RM, Romero-Perez AI, Waterhouse AL & de la Torre-Boronat MC (1995) 
Direct HPLC Analysis of cis- and trans-Resveratrol and Piceid Isomers in Spanish 
Red Vitis vinifera Wines. Journal of Agricultural and Food Chemistry. Vol. 43, No. 2, 
1995):pp. (281-283),  0021-8561 
Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, 
Rock CL & Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC 
Complement Altern Med. Vol. 6, No. 2006):pp. (10),  1472-6882 (Electronic) 
LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG & Selkoe DJ (2005) Dopamine 
covalently modifies and functionally inactivates parkin. Nat Med. Vol. 11, No. 11, 
(Nov 2005):pp. (1214-1221),  1078-8956 (Print) 
Lavoie S, Chen Y, Dalton TP, Gysin R, Cuenod M, Steullet P & Do KQ (2009) Curcumin, 
quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: 
importance of the glutamate cysteine ligase modifier subunit. J Neurochem. Vol. 108, 
No. 6, (Mar 2009):pp. (1410-1422),  1471-4159 (Electronic) 
Leaver KR, Allbutt HN, Creber NJ, Kassiou M & Henderson JM (2009) Oral pre-treatment 
with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle 
symptomatic relief but not neuroprotection. Brain Res Bull. Vol. 80, No. 6, (Dec 16 
2009):pp. (397-402),  1873-2747 (Electronic) 
Lee H, Kim YO, Kim H, Kim SY, Noh HS, Kang SS, Cho GJ, Choi WS & Suk K (2003) 
Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting 
inflammatory activation of microglia. FASEB J. Vol. 17, No. 13, (Oct 2003):pp. (1943-
1944),  1530-6860 (Electronic) 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
142 
Lee MK, Kang SJ, Poncz M, Song KJ & Park KS (2007) Resveratrol protects SH-SY5Y 
neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med. Vol. 39, 
No. 3, (Jun 30 2007):pp. (376-384),  1226-3613 (Print) 
Lee S, Suh S & Kim S (2000) Protective effects of the green tea polyphenol (-)-
epigallocatechin gallate against hippocampal neuronal damage after transient 
global ischemia in gerbils. Neurosci Lett. Vol. 287, No. 3, (Jun 30 2000):pp. (191-194),  
0304-3940 (Print) 
Levites Y, Amit T, Youdim MB & Mandel S (2002a) Involvement of protein kinase C 
activation and cell survival/ cell cycle genes in green tea polyphenol (-)-
epigallocatechin 3-gallate neuroprotective action. J Biol Chem. Vol. 277, No. 34, (Aug 
23 2002a):pp. (30574-30580),  0021-9258 (Print) 
Levites Y, Weinreb O, Maor G, Youdim MB & Mandel S (2001) Green tea polyphenol (-)-
epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced dopaminergic neurodegeneration. J Neurochem. Vol. 78, No. 5, (Sep 
2001):pp. (1073-1082),  0022-3042 (Print) 
Levites Y, Youdim MB, Maor G & Mandel S (2002b) Attenuation of 6-hydroxydopamine (6-
OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by 
tea extracts in neuronal cultures. Biochem Pharmacol. Vol. 63, No. 1, (Jan 1 2002b):pp. 
(21-29),  0006-2952 (Print) 
Li C, Lee MJ, Sheng S, Meng X, Prabhu S, Winnik B, Huang B, Chung JY, Yan S, Ho CT & 
Yang CS (2000) Structural identification of two metabolites of catechins and their 
kinetics in human urine and blood after tea ingestion. Chem Res Toxicol. Vol. 13, No. 
3, (Mar 2000):pp. (177-184),  0893-228X (Print) 
Li R, Huang YG, Fang D & Le WD (2004) (-)-Epigallocatechin gallate inhibits 
lipopolysaccharide-induced microglial activation and protects against 
inflammation-mediated dopaminergic neuronal injury. J Neurosci Res. Vol. 78, No. 
5, (Dec 1 2004):pp. (723-731),  0360-4012 (Print) 
Li R, Peng N, Du F, Li XP & Le WD (2006) Epigallocatechin gallate protects dopaminergic 
neurons against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced 
neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue 
Bao. Vol. 26, No. 4, (Apr 2006):pp. (376-380),  1673-4254 (Print) 
Li X, Jankovic J & Le W (2010) Iron chelation and neuroprotection in neurodegenerative 
diseases. Journal of Neural Transmission. Vol., No. 2010):pp. (1-5),  0300-9564 
Lim GP, Chu T, Yang F, Beech W, Frautschy SA & Cole GM (2001) The curry spice curcumin 
reduces oxidative damage and amyloid pathology in an Alzheimer transgenic 
mouse. J Neurosci. Vol. 21, No. 21, (Nov 1 2001):pp. (8370-8377),  1529-2401 
(Electronic) 
Liou HH, Chen RC, Chen TH, Tsai YF & Tsai MC (2001) Attenuation of paraquat-induced 
dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo. Toxicol Appl 
Pharmacol. Vol. 172, No. 1, (Apr 1 2001):pp. (37-43),  0041-008X (Print) 
Long J, Gao H, Sun L, Liu J & Zhao-Wilson X (2009) Grape extract protects mitochondria 
from oxidative damage and improves locomotor dysfunction and extends lifespan 
in a Drosophila Parkinson's disease model. Rejuvenation Res. Vol. 12, No. 5, (Oct 
2009):pp. (321-331),  1557-8577 (Electronic) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
143 
Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL & Rogan EG (2008) Resveratrol prevents 
estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. 
Cancer Prev Res (Phila). Vol. 1, No. 2, (Jul 2008):pp. (135-145),  1940-6215 (Electronic) 
Luo Y, Hattori A, Munoz J, Qin ZH & Roth GS (1999) Intrastriatal dopamine injection 
induces apoptosis through oxidation-involved activation of transcription factors 
AP-1 and NF-kappaB in rats. Mol Pharmacol. Vol. 56, No. 2, (Aug 1999):pp. (254-
264),  0026-895X (Print) 
Mandel S, Maor G & Youdim MB (2004) Iron and alpha-synuclein in the substantia nigra of 
MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea 
polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci. Vol. 24, No. 3, 2004):pp. 
(401-416),  0895-8696 (Print) 
Mandel SA, Amit T, Kalfon L, Reznichenko L & Youdim MB (2008) Targeting multiple 
neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J 
Nutr. Vol. 138, No. 8, (Aug 2008):pp. (1578S-1583S),  1541-6100 (Electronic) 
Mandel SA, Amit T, Weinreb O & Youdim MB (2011) Understanding the Broad-Spectrum 
Neuroprotective Action Profile of Green Tea Polyphenols in Aging and 
Neurodegenerative Diseases. J Alzheimers Dis. Vol., No. (Mar 2 2011):pp. 1875-8908 
(Electronic) 
Matsuoka Y, Hasegawa H, Okuda S, Muraki T, Uruno T & Kubota K (1995) Ameliorative 
effects of tea catechins on active oxygen-related nerve cell injuries. J Pharmacol Exp 
Ther. Vol. 274, No. 2, (Aug 1995):pp. (602-608),  0022-3565 (Print) 
Matter WF, Brown RF & Vlahos CJ (1992) The inhibition of phosphatidylinositol 3-kinase by 
quercetin and analogs. Biochem Biophys Res Commun. Vol. 186, No. 2, (Jul 31 
1992):pp. (624-631),  0006-291X (Print) 
Mattivi F, Reniero F & Korhammer S (1995) Isolation, Characterization, and Evolution in 
Red Wine Vinification of Resveratrol Monomers. Journal of Agricultural and Food 
Chemistry. Vol. 43, No. 7, 1995):pp. (1820-1823),  0021-8561 
Mattson MP, Son TG & Camandola S (2007) Viewpoint: mechanisms of action and 
therapeutic potential of neurohormetic phytochemicals. Dose Response. Vol. 5, No. 3, 
2007):pp. (174-186),  1559-3258 (Electronic) 
Mazzio E, Huber J, Darling S, Harris N & Soliman KF (2001) Effect of antioxidants on L-
glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 
cells. Neurotoxicology. Vol. 22, No. 2, (Apr 2001):pp. (283-288),  0161-813X (Print) 
Mishra B, Priyadarsini KI, Bhide MK, Kadam RM & Mohan H (2004) Reactions of 
superoxide radicals with curcumin: probable mechanisms by optical spectroscopy 
and EPR. Free Radic Res. Vol. 38, No. 4, (Apr 2004):pp. (355-362),  1071-5762 (Print) 
Moldzio R, Radad K, Krewenka C, Kranner B, Duvigneau JC, Wang Y & Rausch WD (2010) 
Effects of epigallocatechin gallate on rotenone-injured murine brain cultures. J 
Neural Transm. Vol. 117, No. 1, (Jan 2010):pp. (5-12),  1435-1463 (Electronic) 
Molina MF, Sanchez-Reus I, Iglesias I & Benedi J (2003) Quercetin, a flavonoid antioxidant, 
prevents and protects against ethanol-induced oxidative stress in mouse liver. Biol 
Pharm Bull. Vol. 26, No. 10, (Oct 2003):pp. (1398-1402),  0918-6158 (Print) 
Motterlini R, Foresti R, Bassi R & Green CJ (2000) Curcumin, an antioxidant and anti-
inflammatory agent, induces heme oxygenase-1 and protects endothelial cells 
against oxidative stress. Free Radic Biol Med. Vol. 28, No. 8, (Apr 15 2000):pp. (1303-
1312),  0891-5849 (Print) 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
144 
Muthane U, Yasha TC & Shankar SK (1998) Low numbers and no loss of melanized nigral 
neurons with increasing age in normal human brains from India. Ann Neurol. Vol. 
43, No. 3, (Mar 1998):pp. (283-287),  0364-5134 (Print) 
Mythri RB, Harish G, Dubey SK, Misra K & Bharath MM (2011) Glutamoyl diester of the 
dietary polyphenol curcumin offers improved protection against peroxynitrite-
mediated nitrosative stress and damage of brain mitochondria in vitro: implications 
for Parkinson's disease. Mol Cell Biochem. Vol. 347, No. 1-2, (Jan 2011):pp. (135-143),  
1573-4919 (Electronic) 
Mythri RB, Jagatha B, Pradhan N, Andersen J & Bharath MM (2007) Mitochondrial complex 
I inhibition in Parkinson's disease: how can curcumin protect mitochondria? 
Antioxid Redox Signal. Vol. 9, No. 3, (Mar 2007):pp. (399-408),  1523-0864 (Print) 
Nie G, Cao Y & Zhao B (2002) Protective effects of green tea polyphenols and their major 
component, (-)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced 
apoptosis in PC12 cells. Redox Rep. Vol. 7, No. 3, 2002):pp. (171-177),  1351-0002 
(Print) 
North BJ & Verdin E (2004) Sirtuins: Sir2-related NAD-dependent protein deacetylases. 
Genome Biol. Vol. 5, No. 5, 2004):pp. (224),  1465-6914 (Electronic) 
Ohara K, Mizukami, W., Tokunaga, A., Nagaoka, S., Uno, H., and Mukai (2005) Kinetic 
Study of the Mechanism of Free-Radical Scavenging Action in Curcumin: Effects of 
Solvent and pH. Bull Chem Soc Jpn. Vol. 78, No. 4, 2005):pp. (615-621),  0009-2673 
Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T & Akaike A (2007) Resveratrol 
protects dopaminergic neurons in midbrain slice culture from multiple insults. 
Biochem Pharmacol. Vol. 73, No. 4, (Feb 15 2007):pp. (550-560),  0006-2952 (Print) 
Oliver CN, Starke-Reed PE, Stadtman ER, Liu GJ, Carney JM & Floyd RA (1990) Oxidative 
damage to brain proteins, loss of glutamine synthetase activity, and production of 
free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl 
Acad Sci U S A. Vol. 87, No. 13, (Jul 1990):pp. (5144-5147),  0027-8424 (Print) 
Ono K & Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-
destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem. Vol. 97, No. 1, 
(Apr 2006):pp. (105-115),  0022-3042 (Print) 
Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, 
Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT 
& Kazantsev AG (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated 
toxicity in models of Parkinson's disease. Science. Vol. 317, No. 5837, (Jul 27 
2007):pp. (516-519),  1095-9203 (Electronic) 
Pallas M, Casadesus G, Smith MA, Coto-Montes A, Pelegri C, Vilaplana J & Camins A (2009) 
Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential 
pathway towards neuroprotection. Curr Neurovasc Res. Vol. 6, No. 1, (Feb 2009):pp. 
(70-81),  1875-5739 (Electronic) 
Pallas M, Verdaguer E, Tajes M, Gutierrez-Cuesta J & Camins A (2008) Modulation of 
sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov. Vol. 3, No. 1, (Jan 
2008):pp. (61-69),  1574-8898 (Print) 
Pan MH, Huang TM & Lin JK (1999) Biotransformation of curcumin through reduction and 
glucuronidation in mice. Drug Metab Dispos. Vol. 27, No. 4, (Apr 1999):pp. (486-494),  
0090-9556 (Print) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
145 
Pan MH, Lin-Shiau SY & Lin JK (2000) Comparative studies on the suppression of nitric 
oxide synthase by curcumin and its hydrogenated metabolites through down-
regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem 
Pharmacol. Vol. 60, No. 11, (Dec 1 2000):pp. (1665-1676),  0006-2952 (Print) 
Pan T, Jankovic J & Le W (2003) Potential therapeutic properties of green tea polyphenols in 
Parkinson's disease. Drugs Aging. Vol. 20, No. 10, 2003):pp. (711-721),  1170-229X 
(Print) 
Pandey N, Strider J, Nolan WC, Yan SX & Galvin JE (2008) Curcumin inhibits aggregation of 
alpha-synuclein. Acta Neuropathol. Vol. 115, No. 4, (Apr 2008):pp. (479-489),  0001-
6322 (Print) 
Peeyush KT, Gireesh G, Jobin M & Paulose CS (2009) Neuroprotective role of curcumin in 
the cerebellum of streptozotocin-induced diabetic rats. Life Sci. Vol. 85, No. 19-20, 
(Nov 4 2009):pp. (704-710),  1879-0631 (Electronic) 
Pietta PG, Simonetti P, Gardana C, Brusamolino A, Morazzoni P & Bombardelli E (1998) 
Catechin metabolites after intake of green tea infusions. Biofactors. Vol. 8, No. 1-2, 
1998):pp. (111-118),  0951-6433 (Print) 
Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S & Howells L 
(1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the 
chemopreventive agent curcumin involves inhibition of NF-kappaB activation via 
the NIK/IKK signalling complex. Oncogene. Vol. 18, No. 44, (Oct 28 1999):pp. (6013-
6020),  0950-9232 (Print) 
Priyadarsini KI, Maity DK, Naik GH, Kumar MS, Unnikrishnan MK, Satav JG & Mohan H 
(2003) Role of phenolic O-H and methylene hydrogen on the free radical reactions 
and antioxidant activity of curcumin. Free Radic Biol Med. Vol. 35, No. 5, (Sep 1 
2003):pp. (475-484),  0891-5849 (Print) 
Qureshi S, Shah AH & Ageel AM (1992) Toxicity studies on Alpinia galanga and Curcuma 
longa. Planta Med. Vol. 58, No. 2, (Apr 1992):pp. (124-127),  0032-0943 (Print) 
Rajeswari A (2006) Curcumin protects mouse brain from oxidative stress caused by 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur Rev Med Pharmacol Sci. Vol. 10, No. 
4, (Jul-Aug 2006):pp. (157-161),  1128-3602 (Print) 
Rajeswari A & Sabesan M (2008) Inhibition of monoamine oxidase-B by the polyphenolic 
compound, curcumin and its metabolite tetrahydrocurcumin, in a model of 
Parkinson's disease induced by MPTP neurodegeneration in mice. 
Inflammopharmacology. Vol. 16, No. 2, (Apr 2008):pp. (96-99),  0925-4692 (Print) 
Ramassamy C (2006) Emerging role of polyphenolic compounds in the treatment of 
neurodegenerative diseases: A review of their intracellular targets. Eur J Pharmacol 
Vol. 545, No. 1, (Sep 2006): pp (51–64) 
Ray B, Bisht S, Maitra A & Lahiri DK (2011) Neuroprotective and neurorescue effects of a 
novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal 
cell culture and animal model: implications for Alzheimer's disease. J Alzheimers 
Dis. Vol. 23, No. 1, (Jan 1 2011):pp. (61-77),  1875-8908 (Electronic) 
Raza H, John A, Brown EM, Benedict S & Kambal A (2008) Alterations in mitochondrial 
respiratory functions, redox metabolism and apoptosis by oxidant 4-
hydroxynonenal and antioxidants curcumin and melatonin in PC12 cells. Toxicol 
Appl Pharmacol. Vol. 226, No. 2, (Jan 15 2008):pp. (161-168),  0041-008X (Print) 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
146 
Revuelta MP, Cantabrana B & Hidalgo A (1997) Depolarization-dependent effect of 
flavonoids in rat uterine smooth muscle contraction elicited by CaCl2. Gen 
Pharmacol. Vol. 29, No. 5, (Nov 1997):pp. (847-857),  0306-3623 (Print) 
Rice-Evans CA & Miller NJ (1996) Antioxidant activities of flavonoids as bioactive 
components of food. Biochem Soc Trans. Vol. 24, No. 3, (Aug 1996):pp. (790-795),  
0300-5127 (Print) 
Rice-Evans CA, Miller NJ & Paganga G (1996) Structure-antioxidant activity relationships of 
flavonoids and phenolic acids. Free Radic Biol Med. Vol. 20, No. 7, 1996):pp. (933-
956),  0891-5849 (Print) 
Richard T, Pawlus AD, Iglesias ML, Pedrot E, Waffo-Teguo P, Merillon JM & Monti JP 
(2011) Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci. 
Vol. 1215, No. (Jan 2011):pp. (103-108),  1749-6632 (Electronic) 
Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K & Youdim MB (1989) 
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J 
Neurochem. Vol. 52, No. 2, (Feb 1989):pp. (515-520),  0022-3042 (Print) 
Rocha-Gonzalez HI, Ambriz-Tututi M & Granados-Soto V (2008) Resveratrol: a natural 
compound with pharmacological potential in neurodegenerative diseases. CNS 
Neurosci Ther. Vol. 14, No. 3, (Fall 2008):pp. (234-247),  1755-5930 (Print) 
Sahu SC & Gray GC (1997) Lipid peroxidation and DNA damage induced by morin and 
naringenin in isolated rat liver nuclei. Food Chem Toxicol. Vol. 35, No. 5, (May 
1997):pp. (443-447),  0278-6915 (Print) 
Saiko P, Szakmary A, Jaeger W & Szekeres T (2008) Resveratrol and its analogs: defense 
against cancer, coronary disease and neurodegenerative maladies or just a fad? 
Mutat Res. Vol. 658, No. 1-2, (Jan-Feb 2008):pp. (68-94),  0027-5107 (Print) 
Sawada H, Ibi M, Kihara T, Honda K, Nakamizo T, Kanki R, Nakanishi M, Sakka N, Akaike 
A & Shimohama S (2002) Estradiol protects dopaminergic neurons in a 
MPP+Parkinson's disease model. Neuropharmacology. Vol. 42, No. 8, (Jun 2002):pp. 
(1056-1064),  0028-3908 (Print) 
Scalbert A & Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr. 
Vol. 130, No. 8S Suppl, (Aug 2000):pp. (2073S-2085S),  0022-3166 (Print) 
Schroeter H, Bahia P, Spencer JP, Sheppard O, Rattray M, Cadenas E, Rice-Evans C & 
Williams RJ (2007) (-)Epicatechin stimulates ERK-dependent cyclic AMP response 
element activity and up-regulates GluR2 in cortical neurons. J Neurochem. Vol. 101, 
No. 6, (Jun 2007):pp. (1596-1606),  0022-3042 (Print) 
Schroeter H, Boyd C, Spencer JP, Williams RJ, Cadenas E & Rice-Evans C (2002) MAPK 
signaling in neurodegeneration: influences of flavonoids and of nitric oxide. 
Neurobiol Aging. Vol. 23, No. 5, (Sep-Oct 2002):pp. (861-880),  0197-4580 (Print) 
Schroeter H, Spencer JP, Rice-Evans C & Williams RJ (2001) Flavonoids protect neurons 
from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun N-
terminal kinase (JNK), c-Jun and caspase-3. Biochem J. Vol. 358, No. Pt 3, (Sep 15 
2001):pp. (547-557),  0264-6021 (Print) 
Schroeter H, Williams RJ, Matin R, Iversen L & Rice-Evans CA (2000) Phenolic antioxidants 
attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. 
Free Radic Biol Med. Vol. 29, No. 12, (Dec 15 2000):pp. (1222-1233),  0891-5849 (Print) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
147 
Shankar TN, Shantha NV, Ramesh HP, Murthy IA & Murthy VS (1980) Toxicity studies on 
turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. 
Indian J Exp Biol. Vol. 18, No. 1, (Jan 1980):pp. (73-75),  0019-5189 (Print) 
Sharma S, Kulkarni SK, Agrewala JN & Chopra K (2006) Curcumin attenuates thermal 
hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol. Vol. 
536, No. 3, (May 1 2006):pp. (256-261),  0014-2999 (Print) 
Shen SC, Lee WR, Lin HY, Huang HC, Ko CH, Yang LL & Chen YC (2002) In vitro and in 
vivo inhibitory activities of rutin, wogonin, and quercetin on lipopolysaccharide-
induced nitric oxide and prostaglandin E(2) production. Eur J Pharmacol. Vol. 446, 
No. 1-3, (Jun 20 2002):pp. (187-194),  0014-2999 (Print) 
Shen SQ, Zhang Y, Xiang JJ & Xiong CL (2007) Protective effect of curcumin against liver 
warm ischemia/reperfusion injury in rat model is associated with regulation of 
heat shock protein and antioxidant enzymes. World J Gastroenterol. Vol. 13, No. 13, 
(Apr 7 2007):pp. (1953-1961),  1007-9327 (Print) 
Shishodia S, Sethi G & Aggarwal BB (2005) Curcumin: getting back to the roots. Ann N Y 
Acad Sci. Vol. 1056, No. (Nov 2005):pp. (206-217),  0077-8923 (Print) 
Shoba G, Joy D, Joseph T, Majeed M, Rajendran R & Srinivas PS (1998) Influence of piperine 
on the pharmacokinetics of curcumin in animals and human volunteers. Planta 
Med. Vol. 64, No. 4, (May 1998):pp. (353-356),  0032-0943 (Print) 
Sinha R, Anderson DE, McDonald SS & Greenwald P (2003) Cancer risk and diet in India. J 
Postgrad Med. Vol. 49, No. 3, (Jul-Sep 2003):pp. (222-228),  0022-3859 (Print) 
Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G & Youdim MB 
(1988) Increased iron (III) and total iron content in post mortem substantia nigra of 
parkinsonian brain. J Neural Transm. Vol. 74, No. 3, 1988):pp. (199-205),  0300-9564 
(Print) 
Spencer JP (2003) Metabolism of tea flavonoids in the gastrointestinal tract. J Nutr. Vol. 133, 
No. 10, (Oct 2003):pp. (3255S-3261S),  0022-3166 (Print) 
Spencer JP (2007) The interactions of flavonoids within neuronal signalling pathways. Genes 
Nutr. Vol. 2, No. 3, (Dec 2007):pp. (257-273),  1555-8932 (Print) 
Spencer JP, Abd-el-Mohsen MM & Rice-Evans C (2004) Cellular uptake and metabolism of 
flavonoids and their metabolites: implications for their bioactivity. Arch Biochem 
Biophys. Vol. 423, No. 1, (Mar 1 2004):pp. (148-161),  0003-9861 (Print) 
Spencer JP, Rice-Evans C & Williams RJ (2003) Modulation of pro-survival Akt/protein 
kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites 
underlie their action on neuronal viability. J Biol Chem. Vol. 278, No. 37, (Sep 12 
2003):pp. (34783-34793),  0021-9258 (Print) 
Srinivasan K (2005) Plant foods in the management of diabetes mellitus: spices as beneficial 
antidiabetic food adjuncts. Int J Food Sci Nutr. Vol. 56, No. 6, (Sep 2005):pp. (399-
414),  0963-7486 (Print) 
Stridh MH, Correa F, Nodin C, Weber SG, Blomstrand F, Nilsson M & Sandberg M (2010) 
Enhanced glutathione efflux from astrocytes in culture by low extracellular ca(2+) 
and curcumin. Neurochem Res. Vol. 35, No. 8, (Aug 2010):pp. (1231-1238),  1573-6903 
(Electronic) 
Sugihara N, Arakawa T, Ohnishi M & Furuno K (1999) Anti- and pro-oxidative effects of 
flavonoids on metal-induced lipid hydroperoxide-dependent lipid peroxidation in 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
148 
cultured hepatocytes loaded with alpha-linolenic acid. Free Radic Biol Med. Vol. 27, 
No. 11-12, (Dec 1999):pp. (1313-1323),  0891-5849 (Print) 
Suresh D & Srinivasan K (2010) Tissue distribution & elimination of capsaicin, piperine & 
curcumin following oral intake in rats. Indian J Med Res. Vol. 131, No. (May 
2010):pp. (682-691),  0971-5916 (Print) 
Tai KK & Truong DD (2010) (-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, 
reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in 
dopaminergic SHSY-5Y cells. Neurosci Lett. Vol. 482, No. 3, (Oct 4 2010):pp. (183-
187),  1872-7972 (Electronic) 
Tan EK, Tan C, Fook-Chong SMC, Lum SY, Chai A, Chung H, Shen H, Zhao Y, Teoh ML, 
Yih Y, Pavanni R, Chandran VR & Wong MC (2003) Dose-dependent protective 
effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. 
Journal of the neurological sciences. Vol. 216, No. 1, 2003):pp. (163-167),  0022-510X 
Tan LC, Koh W-P, Yuan J-M, Wang R, Au W-L, Tan JH, Tan E-K & Yu MC (2008) 
Differential Effects of Black versus Green Tea on Risk of Parkinson's Disease in the 
Singapore Chinese Health Study. American Journal of Epidemiology. Vol. 167, No. 5, 
(March 1, 2008 2008):pp. (553-560),   
Thaloor D, Miller KJ, Gephart J, Mitchell PO & Pavlath GK (1999) Systemic administration of 
the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic 
injury. Am J Physiol. Vol. 277, No. 2 Pt 1, (Aug 1999):pp. (C320-329),  0002-9513 
(Print) 
Thiyagarajan M & Sharma SS (2004) Neuroprotective effect of curcumin in middle cerebral 
artery occlusion induced focal cerebral ischemia in rats. Life Sci. Vol. 74, No. 8, (Jan 
9 2004):pp. (969-985),  0024-3205 (Print) 
Toniolo R, Di Narda F, Susmel S, Martelli M, Martelli L & Bontempelli G (2002) Quenching 
of superoxide ions by curcumin. A mechanistic study in acetonitrile. Ann Chim. Vol. 
92, No. 3, (Mar 2002):pp. (281-288),  0003-4592 (Print) 
Tsao R (2010) Chemistry and Biochemistry of Dietary Polyphenols. Nutrients. Vol. 2, No. 12, 
2010):pp. (1231-1246),  2072-6643 
Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y & Osawa T (1999) Activation of stress 
signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal 
is a potential inducer of intracellular peroxide production. J Biol Chem. Vol. 274, No. 
4, (Jan 22 1999):pp. (2234-2242),  0021-9258 (Print) 
Vajragupta O, Boonchoong P, Watanabe H, Tohda M, Kummasud N & Sumanont Y (2003) 
Manganese complexes of curcumin and its derivatives: evaluation for the radical 
scavenging ability and neuroprotective activity. Free Radic Biol Med. Vol. 35, No. 12, 
(Dec 15 2003):pp. (1632-1644),  0891-5849 (Print) 
van Acker SA, de Groot MJ, van den Berg DJ, Tromp MN, Donne-Op den Kelder G, van der 
Vijgh WJ & Bast A (1996) A quantum chemical explanation of the antioxidant 
activity of flavonoids. Chem Res Toxicol. Vol. 9, No. 8, (Dec 1996):pp. (1305-1312),  
0893-228X (Print) 
Vlahos CJ, Matter WF, Hui KY & Brown RF (1994) A specific inhibitor of 
phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
(LY294002). J Biol Chem. Vol. 269, No. 7, (Feb 18 1994):pp. (5241-5248),  0021-9258 
(Print) 
www.intechopen.com
 
Therapeutic Potential of Polyphenols in Parkinson’s Disease 
 
149 
Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci. Vol. 1215, No. (Jan 2011):pp. 
(9-15),  1749-6632 (Electronic) 
Wang F, Nguyen M, Qin FX & Tong Q (2007) SIRT2 deacetylates FOXO3a in response to 
oxidative stress and caloric restriction. Aging Cell. Vol. 6, No. 4, (Aug 2007):pp. (505-
514),  1474-9718 (Print) 
Wang J, Du XX, Jiang H & Xie JX (2009a) Curcumin attenuates 6-hydroxydopamine-induced 
cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 
cells. Biochem Pharmacol. Vol. 78, No. 2, (Jul 15 2009a):pp. (178-183),  1873-2968 
(Electronic) 
Wang MS, Boddapati S, Emadi S & Sierks MR (2010) Curcumin reduces alpha-synuclein 
induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci. Vol. 11, No. 
2010):pp. (57),  1471-2202 (Electronic) 
Wang SL, Li Y, Wen Y, Chen YF, Na LX, Li ST & Sun CH (2009b) Curcumin, a potential 
inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 
adipocytes through NF-kappaB and JNK pathway. Biomed Environ Sci. Vol. 22, No. 
1, (Feb 2009b):pp. (32-39),  0895-3988 (Print) 
Wang Y, Xu H, Fu Q, Ma R & Xiang J (2011) Protective effect of resveratrol derived from 
Polygonum cuspidatum and its liposomal form on nigral cells in Parkinsonian rats. 
J Neurol Sci. Vol., No. (Mar 2 2011):pp. 1878-5883 (Electronic) 
Weinreb O, Mandel S, Amit T & Youdim MB (2004) Neurological mechanisms of green tea 
polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem. Vol. 15, No. 9, 
(Sep 2004):pp. (506-516),  0955-2863 (Print) 
Wenzel E & Somoza V (2005) Metabolism and bioavailability of trans-resveratrol. Mol Nutr 
Food Res. Vol. 49, No. 5, (May 2005):pp. (472-481),  1613-4125 (Print) 
Wild AC, Moinova HR & Mulcahy RT (1999) Regulation of gamma-glutamylcysteine 
synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem. 
Vol. 274, No. 47, (Nov 19 1999):pp. (33627-33636),  0021-9258 (Print) 
Williams RJ, Spencer JP & Rice-Evans C (2004) Flavonoids: antioxidants or signalling 
molecules? Free Radic Biol Med. Vol. 36, No. 7, (Apr 1 2004):pp. (838-849),  0891-5849 
(Print) 
Woo KJ, Lim JH, Suh SI, Kwon YK, Shin SW, Kim SC, Choi YH, Park JW & Kwon TK (2006) 
Differential inhibitory effects of baicalein and baicalin on LPS-induced 
cyclooxygenase-2 expression through inhibition of C/EBPbeta DNA-binding 
activity. Immunobiology. Vol. 211, No. 5, 2006):pp. (359-368),  0171-2985 (Print) 
Xu Y, Ku B, Cui L, Li X, Barish PA, Foster TC & Ogle WO (2007) Curcumin reverses 
impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA 
and brain-derived neurotrophic factor expression in chronically stressed rats. Brain 
Res. Vol. 1162, No. (Aug 8 2007):pp. (9-18),  0006-8993 (Print) 
Xu YX, Pindolia KR, Janakiraman N, Chapman RA & Gautam SC (1997) Curcumin inhibits 
IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in 
bone marrow stromal cells. Hematopathol Mol Hematol. Vol. 11, No. 1, 1997):pp. (49-
62),  1082-8893 (Print) 
Yamamoto H, Schoonjans K & Auwerx J (2007) Sirtuin Functions in Health and Disease. Mol 
Endocrinol. Vol. 21, No. 8, (August 1, 2007 2007):pp. (1745-1755),   
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, 
Glabe CG, Frautschy SA & Cole GM (2005) Curcumin inhibits formation of amyloid 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 
 
150 
beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 
Vol. 280, No. 7, (Feb 18 2005):pp. (5892-5901),  0021-9258 (Print) 
Ye SF, Hou ZQ, Zhong LM & Zhang QQ (2007) Effect of curcumin on the induction of 
glutathione S-transferases and NADP(H):quinone oxidoreductase and its possible 
mechanism of action. Yao Xue Xue Bao. Vol. 42, No. 4, (Apr 2007):pp. (376-380),  
0513-4870 (Print) 
Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER & Mizuno Y (1996) 
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson 
disease. Proc Natl Acad Sci U S A. Vol. 93, No. 7, (Apr 2 1996):pp. (2696-2701),  0027-
8424 (Print) 
Yu S, Zheng W, Xin N, Chi ZH, Wang NQ, Nie YX, Feng WY & Wang ZY (2010) Curcumin 
prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal 
kinase pathway. Rejuvenation Res. Vol. 13, No. 1, (Feb 2010):pp. (55-64),  1557-8577 
(Electronic) 
Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI & Dexter DT (2005) Neuroprotective 
properties of the natural phenolic antioxidants curcumin and naringenin but not 
quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res. Vol. 
39, No. 10, (Oct 2005):pp. (1119-1125),  1071-5762 (Print) 
Zhang F, Shi JS, Zhou H, Wilson B, Hong JS & Gao HM (2010) Resveratrol protects 
dopamine neurons against lipopolysaccharide-induced neurotoxicity through its 
anti-inflammatory actions. Mol Pharmacol. Vol. 78, No. 3, (Sep 1 2010):pp. (466-477),  
1521-0111 (Electronic) 
Zhang L, Chen J & Fu H (1999) Suppression of apoptosis signal-regulating kinase 1-induced 
cell death by 14-3-3 proteins. Proc Natl Acad Sci U S A. Vol. 96, No. 15, (Jul 20 
1999):pp. (8511-8515),  0027-8424 (Print) 
Zhu YG, Chen XC, Chen ZZ, Zeng YQ, Shi GB, Su YH & Peng X (2004) Curcumin protects 
mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. 
Acta Pharmacol Sin. Vol. 25, No. 12, (Dec 2004):pp. (1606-1612),  1671-4083 (Print) 
Zhuang H, Kim YS, Koehler RC & Dore S (2003) Potential mechanism by which resveratrol, 
a red wine constituent, protects neurons. Ann N Y Acad Sci. Vol. 993, No. (May 
2003):pp. (276-286; discussion 287-278),  0077-8923 (Print) 
www.intechopen.com
Towards New Therapies for Parkinson's Disease
Edited by Prof. David Finkelstein
ISBN 978-953-307-463-4
Hard cover, 396 pages
Publisher InTech
Published online 02, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms,
pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed
primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic,
a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration
progresses despite the current therapies until the cell loss is so great that the quality of normal life is
compromised. The dopamine precursor levodopa is the most valuable drug currently available for the
treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around
five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the
mechanisms of degeneration and to develop disease modifying therapies.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Rajeswara Babu Mythri, G. Harish, N. Raghunath and M.M. Srinivas Bharath (2011). Therapeutic Potential of
Polyphenols in Parkinson’s Disease, Towards New Therapies for Parkinson's Disease, Prof. David Finkelstein
(Ed.), ISBN: 978-953-307-463-4, InTech, Available from: http://www.intechopen.com/books/towards-new-
therapies-for-parkinson-s-disease/therapeutic-potential-of-polyphenols-in-parkinson-s-disease
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
